<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Sulthiame monotherapy for epilepsy - Milburn-McNulty, P - 2021 | Cochrane Library</title> <meta content="Sulthiame monotherapy for epilepsy - Milburn-McNulty, P - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010062.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Sulthiame monotherapy for epilepsy - Milburn-McNulty, P - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010062.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010062.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Sulthiame monotherapy for epilepsy" name="citation_title"/> <meta content="Philip Milburn-McNulty" name="citation_author"/> <meta content="Salford Royal Hospital NHS FoundationÂ Trust" name="citation_author_institution"/> <meta content="Mariangela Panebianco" name="citation_author"/> <meta content="Institute of Systems, Molecular and Integrative Biology, University of Liverpool" name="citation_author_institution"/> <meta content="m.panebianco@liverpool.ac.uk" name="citation_author_email"/> <meta content="Anthony G Marson" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD010062.pub3" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/09/23" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010062.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010062.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010062.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anticonvulsants [therapeutic use]; *Epilepsy [drug therapy]; Quality of Life; Randomized Controlled Trials as Topic; *Thiazines [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010062.pub3&amp;doi=10.1002/14651858.CD010062.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010062.pub3&amp;doi=10.1002/14651858.CD010062.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010062.pub3&amp;doi=10.1002/14651858.CD010062.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010062.pub3&amp;doi=10.1002/14651858.CD010062.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010062.pub3&amp;doi=10.1002/14651858.CD010062.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010062.pub3&amp;doi=10.1002/14651858.CD010062.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010062.pub3&amp;doi=10.1002/14651858.CD010062.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010062.pub3&amp;doi=10.1002/14651858.CD010062.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010062.pub3&amp;doi=10.1002/14651858.CD010062.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010062.pub3&amp;doi=10.1002/14651858.CD010062.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010062.pub3&amp;doi=10.1002/14651858.CD010062.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010062.pub3&amp;doi=10.1002/14651858.CD010062.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010062.pub3&amp;doi=10.1002/14651858.CD010062.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010062.pub3&amp;doi=10.1002/14651858.CD010062.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010062.pub3&amp;doi=10.1002/14651858.CD010062.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010062.pub3&amp;doi=10.1002/14651858.CD010062.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010062.pub3&amp;doi=10.1002/14651858.CD010062.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010062.pub3&amp;doi=10.1002/14651858.CD010062.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010062.pub3&amp;doi=10.1002/14651858.CD010062.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010062.pub3&amp;doi=10.1002/14651858.CD010062.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010062.pub3&amp;doi=10.1002/14651858.CD010062.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010062.pub3&amp;doi=10.1002/14651858.CD010062.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010062.pub3&amp;doi=10.1002/14651858.CD010062.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="1ljSZou6";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010062\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010062\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010062\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010062\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fa","fr","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010062.pub3",title:"Sulthiame monotherapy for epilepsy",firstPublishedDate:"Sep 23, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Epilepsy Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1ljSZou6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010062.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010062.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> EspaÃ±ol </option> <option class="content-language-option" data-languagecode="fa" value="fa"> ÙØ§Ø±Ø³Û </option> <option class="content-language-option" data-languagecode="fr" value="fr"> FranÃ§ais </option> <option class="content-language-option" data-languagecode="hi" value="hi"> à¤¹à¤¿à¤¨à¥à¤¦à¥ </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> æ¥æ¬èª </option> <option class="content-language-option" data-languagecode="ko" value="ko"> íêµ­ì´ </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> PortuguÃªs </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Ð ÑÑÑÐºÐ¸Ð¹ </option> <option class="content-language-option" data-languagecode="ro" value="ro"> RomÃ¢nÄ </option> <option class="content-language-option" data-languagecode="ta" value="ta"> à®¤à®®à®¿à®´à¯ </option> <option class="content-language-option" data-languagecode="th" value="th"> à¸ à¸²à¸©à¸²à¹à¸à¸¢ </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> ç¹é«ä¸­æ </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> ç®ä½ä¸­æ </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010062.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010062.pub3/full/es"> EspaÃ±ol </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010062.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010062.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;ÚÚ©ÛØ¯Ù&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;RÃ©sumÃ© scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en tÃ©rminos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;Ø®ÙØ§ØµÙ Ø¨Ù Ø²Ø¨Ø§Ù Ø³Ø§Ø¯Ù&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;RÃ©sumÃ© simplifiÃ©&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010062.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010062.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010062.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010062.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views:Â </span> <span>1195 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010062.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010062.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010062.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010062.pub3/full#CD010062-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010062.pub3/full#CD010062-sec-0081"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010062.pub3/full#CD010062-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010062.pub3/full#CD010062-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010062.pub3/full#CD010062-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010062.pub3/full#CD010062-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010062.pub3/full#CD010062-sec-0042"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010062.pub3/full#CD010062-sec-0075"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010062.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010062.pub3/appendices#CD010062-sec-0086"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010062.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010062.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/supinfo/CD010062StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/supinfo/CD010062StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010062.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010062.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010062.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010062.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010062.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010062.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright Â© 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Sulthiame monotherapy for epilepsy</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010062.pub3/information#CD010062-cr-0004">Philip Milburn-McNulty</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010062.pub3/information#CD010062-cr-0005"><i class="icon corresponding-author fa fa-envelope"></i>Mariangela Panebianco</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010062.pub3/information#CD010062-cr-0006">Anthony G Marson</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/information/en#CD010062-sec-0093">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 23 September 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010062.pub3">https://doi.org/10.1002/14651858.CD010062.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010062-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010062-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010062-abs-0008">EspaÃ±ol</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010062-abs-0003">ÙØ§Ø±Ø³Û</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010062-abs-0005">FranÃ§ais</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010062-abs-0001" lang="en"> <section id="CD010062-sec-0001"> <h3 class="title" id="CD010062-sec-0001">Background</h3> <p>This is an updated version of the original Cochrane Review published in 2014.</p> <p>Epilepsy is a common neurological condition characterised by recurrent seizures. Pharmacological treatment remains the first choice to control epilepsy. Sulthiame (STM) is widely used as an antiepileptic drug in Europe and Israel. In this review, we have presented a summary of evidence for the use of STM as monotherapy in epilepsy. </p> </section> <section id="CD010062-sec-0002"> <h3 class="title" id="CD010062-sec-0002">Objectives</h3> <p>To assess the efficacy and side effect profile of STM as monotherapy when compared with placebo or another antiepileptic drug for people with epilepsy. </p> </section> <section id="CD010062-sec-0003"> <h3 class="title" id="CD010062-sec-0003">Search methods</h3> <p>We searched the following databases on 13 April 2020: the Cochrane Register of Studies (CRS Web), MEDLINE (Ovid, 1946 to 10 April 2020). CRS Web includes randomised or quasiârandomised controlled trials from PubMed, Embase, ClinicalTrials.gov, the World Health Organization International Clinical Trials Registry Platform, the Cochrane Central Register of Controlled Trials (CENTRAL), and the specialised registers of Cochrane Review Groups including Cochrane Epilepsy. We imposed no language restrictions. We contacted the manufacturers of STM and researchers in the field to ask about ongoing and unpublished studies. </p> </section> <section id="CD010062-sec-0004"> <h3 class="title" id="CD010062-sec-0004">Selection criteria</h3> <p>Randomised controlled monotherapy trials of STM in people of any age with epilepsy of any aetiology. </p> </section> <section id="CD010062-sec-0005"> <h3 class="title" id="CD010062-sec-0005">Data collection and analysis</h3> <p>We followed standard Cochrane methodology. Two review authors independently selected trials for inclusion and extracted the relevant data. We assessed the following outcomes: treatment withdrawal; seizureâfree at six months; adverse effects; and quality of life scoring. We conducted the primary analyses by intentionâtoâtreat where possible, and presented a narrative analysis of the data. </p> </section> <section id="CD010062-sec-0006"> <h3 class="title" id="CD010062-sec-0006">Main results</h3> <p>We included four studies involving a total of 355 participants: three studies (209 participants) with a diagnosis of benign epilepsy of childhood with centrotemporal spikes (BECTS), and one study (146 participants) with a diagnosis of generalised tonicâclonic seizures (GTCS). STM was given as monotherapy compared with placebo and with levetiracetam in the BECTS studies, and compared with phenytoin in the GTCS study. An English translation of the full text of one of the BECTS studies could not be found, and analysis of this study was based solely on the English translation of the abstract. </p> <p>For the primary outcome, the total number of dropouts caused either by seizure recurrence or adverse reaction was significantly higher in the levetiracetam treatment arm compared to the STM treatment arm (RR 0.32, 95% Cl 0.10 to 1.03; 1 study, 43 participants; lowâcertainty evidence). For the secondary outcomes for this comparison, results for seizure freedom were inconclusive (RR 1.12, 95% Cl 0.88 to 1.44; 1 study, 43 participants; lowâcertainty evidence). </p> <p>Reporting of adverse effects was incomplete. Participants receiving STM were significantly less likely to develop gingival hyperplasia than participants receiving phenytoin in the GTCS study (RR 0.03, 95% CI 0.00 to 0.58; 1 study, 146 participants; lowâcertainty evidence). No further statistically significant adverse events were noted when STM was compared with phenytoin or placebo. The most common adverse events were related to behavioural disturbances when STM was compared with levetiracetam (RR 0.95, 95% Cl 0.59 to 1.55; 1 study, 43 participants; lowâcertainty evidence), with the same incidence in both groups. No data were reported for quality of life. </p> <p>Overall, we assessed one study at high risk of bias and one study at unclear bias across the seven domains, mainly due to lack of information regarding study design. Only one trial reported effective methods for blinding. The risk of bias assessments for the other two studies ranged from low to high. We rated the overall certainty of the evidence for the outcomes as low using the GRADE approach. </p> </section> <section id="CD010062-sec-0007"> <h3 class="title" id="CD010062-sec-0007">Authors' conclusions</h3> <p>This review provides insufficient information to inform clinical practice. Small sample sizes, poor methodological quality, and lack of data on important outcome measures precluded any meaningful conclusions regarding the efficacy and tolerability of sulthiame as monotherapy in epilepsy. More trials, recruiting larger populations, over longer periods, are needed to determine whether sulthiame has a clinical use. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010062-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010062-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010062-abs-0009">EspaÃ±ol</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010062-abs-0004">ÙØ§Ø±Ø³Û</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010062-abs-0006">FranÃ§ais</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010062-abs-0007">Bahasa Malaysia</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010062-abs-0002" lang="en"> <h3>Sulthiame monotherapy for epilepsyÂ </h3> <p><b>Background</b> </p> <p>Epilepsy is a common neurological condition characterised by recurrent seizures. Sulthiame (STM) is widely used as an antiepileptic drug in Europe and Israel. </p> <p><b>Review aims</b> </p> <p>This review aimed to determine the efficacy and side effect profile of STM as monotherapy, when compared with placebo or another antiepileptic drug for people with epilepsy. </p> <p><b>Results</b> </p> <p>We found four randomised controlled trials (studies in which participants are randomly assigned to one of two or more treatment groups) involving a total of 355 participants that looked at the effectiveness and tolerability of sulthiame used as a single treatment in epilepsy. Three studies were conducted on a common form of childhood epilepsy known as benign epilepsy of childhood with centrotemporal spikes, and one study was conducted on generalised tonicâclonic seizures, a type of seizure that starts on both sides of the brain and causes stiffness or twitching throughout the body. Based on the available evidence, we could draw no meaningful conclusions on the effectiveness or tolerability of sulthiame as a single treatment in epilepsy. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of the evidence is limited by small sizes of the groups being studied, significant risk of bias, and incomplete data on important outcome measures, as well as by the lack of an English translation of the fullâtext manuscript of one study. </p> <p><b>Conclusions</b> </p> <p>Further highâquality research is needed to fully evaluate the effectiveness and tolerability of sulthiame as a single treatment in epilepsy. </p> <p>The evidence is current to April 2020.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010062-sec-0081" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010062-sec-0081"></div> <h3 class="title" id="CD010062-sec-0082">Implications for practice</h3> <section id="CD010062-sec-0082"> <p>We could draw no meaningful conclusions regarding the efficacy or safety of sulthiame as monotherapy in epilepsy based on the available evidence. </p> </section> <h3 class="title" id="CD010062-sec-0083">Implications for research</h3> <section id="CD010062-sec-0083"> <p>Studies should report data on time to treatment withdrawal; proportion of participants achieving a reduction in seizure frequency of 50% or greater; proportion of participants seizureâfree at 12 months; and quality of life scale scores, in addition to adverse effects, to facilitate meaningful metaâanalysis. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010062-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010062-sec-0008"></div> <div class="table" id="CD010062-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span>Â <span class="table-title">Sulthiame compared to placebo for epilepsy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Sulthiame compared to placebo for epilepsy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with epilepsy </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> sulthiame </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sulthiame</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment withdrawal</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 (2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for treatment withdrawal not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizure freedom</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 (2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for seizure freedom not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All adverse effects</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 (2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for adverse effects not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b><sup>1</sup>(e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>N/A:</b> not applicable </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Assumed risk is calculated as the event rate in the control group per 1000 people (number of events divided by the number of participants receiving control treatment). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010062-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span>Â <span class="table-title">Sulthiame compared with levetiracetam for epilepsy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Sulthiame compared with levetiracetam for epilepsy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with epilepsy (BECTS) </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> sulthiame </p> <p><b>Comparison:</b> levetiracetam </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sulthiame</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment withdrawal</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>429 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>137 per 1000</b> </p> <p>(43 to 442)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.32</b> (0.10 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single, small study. Data for number of treatment withdrawal provided.</p> <p>RR &lt; 1 indicates outcome is more likely in control group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizure freedom</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>809 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>906 per 1000</b> </p> <p>(712 to 1165)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b> </p> <p>(0.88 to 1.44)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ</p> <p><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single, small study. Data for seizure freedom provided.</p> <p>RR &gt; 1 indicates outcome is more likely in sulthiame group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects (general symptoms)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>714 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>771 per 1000</b> </p> <p>(543 to 1100)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b> (0.76 to 1.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single, small study. Data for number of adverse events provided.</p> <p>RR &gt; 1 indicates outcome is more likely in sulthiame group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects (central nervous system)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>619 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>724 per 1000</b> </p> <p>(477 to 1108)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.17</b> (0.77 to 1.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single, small study. Data for number of adverse</p> <p>events provided.</p> <p>RR &gt; 1 indicates outcome is more likely in sulthiame</p> <p>group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects (behaviour)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>619 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>588 per 1000</b> </p> <p>(365 to 959)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b> (0.59 to 1.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single, small study. Data for number of adverse events provided.</p> <p>RR &lt; 1 indicates outcome is more likely in control</p> <p>group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects (airways)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>238 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>636 per 1000</b> </p> <p>(279 to 1457)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.67</b> (1.17 to 6.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single, small study. Data for number of adverse</p> <p>events provided.</p> <p>RR &gt; 1 indicates outcome is more likely in sulthiame</p> <p>group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects (cardiac)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> <p>(0 to 0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.87</b> (0.12 to 66.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single, small study. Data for number of adverse</p> <p>events provided.</p> <p>RR &gt; 1 indicates outcome is more likely in sulthiame</p> <p>group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects (gastrointestinal)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>576 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>438 per 1000</b> </p> <p>(213 to 899)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.76</b> (0.37 to 1.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single, small study. Data for number of adverse</p> <p>events provided.</p> <p>RR &lt; 1 indicates outcome is more likely in control</p> <p>group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects (bones and muscles)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>191 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>182 per 1000</b> </p> <p>(52 to 636)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b> (0.27 to 3.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single, small study. Data for number of adverse events provided.</p> <p>RR &lt; 1 indicates outcome is more likely in control</p> <p>group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects (others)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>191 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>227 per 1000</b> </p> <p>(71 to 735)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.19</b> (0.37 to 3.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single, small study. Data for number of adverse events provided.</p> <p>RR &gt; 1 indicates outcome is more likely in sulthiame</p> <p>group.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b><sup>3</sup> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>BECTS:</b> benign epilepsy of childhood with centrotemporal spikes; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded once for risk of bias: some included studies had incomplete methodological information.<br/><sup>2</sup>Downgraded once for imprecision: number of events does not suffice for optimal information size.<br/><sup>3</sup>Assumed risk is calculated as the event rate in the control group per 1000 people (number of events divided by the number of participants receiving control treatment). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010062-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span>Â <span class="table-title">Sulthiame compared with phenytoin for epilepsy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Sulthiame compared with phenytoin for epilepsy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with epilepsy (GTCS) </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> sulthiame </p> <p><b>Comparison:</b> phenytoin </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sulthiame</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment withdrawal</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> <p>(0 to 0)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> <p>(0 to 0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for treatment withdrawal not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizure freedom</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for seizure freedom not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All adverse effects</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>250 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>263 per 1000</b><br/>(135 to 517) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b> (0.54 to 2.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single study. Data for number of adverse events provided. Unclear if data on adverse events reflect number of events or number of participants experiencing an event. </p> <p>RR &gt; 1 indicates outcome is more likely in sulthiame group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Paraesthesia</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>123 per 1000</b><br/>(0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 8.32</b> (0.51 to 135.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single study. Data for number of adverse events provided. Unclear if data on adverse events reflect number of events or number of participants experiencing an event. </p> <p>RR &gt; 1 indicates outcome is more likely in sulthiame group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dizziness</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 1000</b><br/>(0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.16</b> (0.18 to 55.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single study. Data for number of adverse events provided. Unclear if data on adverse events reflect number of events or number of participants experiencing an event. </p> <p>RR &gt; 1 indicates outcome is more likely in sulthiame group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Headache</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b><br/>(0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.43</b> (0.07 to 29.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single study. Data for number of adverse events provided. Unclear if data on adverse events reflect number of events or number of participants experiencing an event. </p> <p>RR &gt; 1 indicates outcome is more likely in sulthiame group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Anorexia</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>63 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>26 per 1000</b><br/>(4 to 152) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.42</b> (0.07 to 2.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single study. Data for number of adverse events provided. Unclear if data on adverse events reflect number of events or number of participants experiencing an event. </p> <p>RR &lt; 1 indicates outcome is more likely in control group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rash</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b><br/>(1 to 135) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.28</b> (0.02 to 4.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single study. Data for number of adverse events provided. Unclear if data on adverse events reflect number of events or number of participants experiencing an event. </p> <p>RR &lt; 1 indicates outcome is more likely in control group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gingival hyperplasia</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>125 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b><br/>(0 to 72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.03</b> (0.00 to 0.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single study. Data for number of adverse events provided. Unclear if data on adverse events reflect number of events or number of participants experiencing an event. </p> <p>RR &lt; 1 indicates outcome is more likely in control group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>43 per 1000</b><br/>(5 to 359) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.40</b> (0.17 to 11.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single study. Data for number of adverse events provided. Unclear if data on adverse events reflect number of events or number of participants experiencing an event. </p> <p>RR &gt; 1 indicates outcome is more likely in sulthiame group.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b><sup>3</sup>(e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>GTCS:</b> generalised tonicâclonic seizures; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded once for risk of bias: one included study had incomplete methodological information.<br/><sup>2</sup>Downgraded once for imprecision: number of events does not suffice for optimal information size.<br/><sup>3</sup>Assumed risk is calculated as the event rate in the control group per 1000 people (number of events divided by the number of participants receiving control treatment). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010062-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010062-sec-0009"></div> <p>This review is an update of a Cochrane Review previously published in 2014 (<a href="./references#CD010062-bbs2-0044" title="Milburn-McNultyP , PowellG , SillsGJ , MarsonAG . Sulthiame monotherapy for epilepsy. Cochrane Database of Systematic Reviews2014, Issue 3. Art. No: CD010062. [DOI: 10.1002/14651858.CD010062.pub2]">MilburnâMcNulty 2014</a>). </p> <section id="CD010062-sec-0010"> <h3 class="title" id="CD010062-sec-0010">Description of the condition</h3> <p>Epilepsy is a common neurological condition characterised by recurrent seizures. It has an estimated worldwide prevalence of between eight and 10 per 1000 of the general population (<a href="./references#CD010062-bbs2-0040" title="World Health Organization. Epilepsy: Aetiology, Epidemiology and Prognosis. Geneva: World Health Organization, 2001.">WHO 2001</a>). Most people with epilepsy will respond well to conventional antiepileptic drugs (AEDs) (<a href="./references#CD010062-bbs2-0024" title="International League Against Epilepsy. ILAE Commission Report. The epidemiology of the epilepsies: future directions. Epilepsia1997;38(5):614-8. [PMID: 9184609]">ILAE 1997</a>), although around 30% will not achieve remission despite trying numerous AEDs, often in combination (<a href="./references#CD010062-bbs2-0035" title="SanderJW . Some aspects of prognosis in the epilepsies: a review. Epilepsia1993;34(6):1007-16. [PMID: 8243349]">Sander 1993</a>; <a href="./references#CD010062-bbs2-0036" title="SchmidtD , GramL . Monotherapy versus polytherapy in epilepsy: a reappraisal. CNS Drugs1995;3:194-208. [DOI: 10.2165/00023210-199503030-00005]">Schmidt 1995</a>; <a href="./references#CD010062-bbs2-0015" title="BrodieMJ , DichterMA . Antiepileptic drugs. New England Journal of Medicine1996;334(3):168-75. [PMID: 8531974]">Brodie 1996</a>). </p> </section> <section id="CD010062-sec-0011"> <h3 class="title" id="CD010062-sec-0011">Description of the intervention</h3> <p>Sulthiame (STM) is a sulphonamide that is usually taken two to three times per day in tablet form. STM was initially investigated for use in epilepsy in clinical trials in the 1960s (<a href="./references#CD010062-bbs2-0006" title="GriffithsAW , SylvesterPE . Ospolot - a clinical trial of a new anticonvulsant. British Journal of Psychiatry1964;110:261-6. [DOI: 10.1192/bjp.110.465.261] [PMID: 14130479]">Griffiths 1964</a>), but was never licenced widely as a treatment for epilepsy. However, it is currently widely used as an AED in some European countries and in Israel (<a href="./references#CD010062-bbs2-0021" title="Gross-SelbeckG . Current treatment strategies for childhood seizures and epilepsy [Derzeitige behandlungsstrategien bei anfÃ¤llen und epilepsien im kindesalter]. Monatsschrift fur Kinderheilkunde2001;149(11):1174-9. [DOI: 10.1007/s001120170041]">GrossâSelbeck 2001</a>; <a href="./references#CD010062-bbs2-0026" title="KoeppMJ , PatsalosPN , SanderJWAS . Sulthiame in adults with refractory epilepsy and learning disability: an open trial. Epilepsy Research2002;50(3):277-82. [PMID: 12200218]">Koepp 2002</a>; <a href="./references#CD010062-bbs2-0018" title="EnglerF , Maeder-IngvarM , RouletE , DeonnaT . Treatment with sulthiame (ospolot) in benign partial epilepsy of childhood and related syndromes: an open clinical and EEG study. Neuropediatrics2003;34(2):105-9. [PMID: 12776234]">Engler 2003</a>; <a href="./references#CD010062-bbs2-0013" title="Ben-ZeevB , WatembergN , LermanP , BarashI , BrandN , Lerman-SagieT . Sulthiame in childhood epilepsy. Paediatrics International2004;46(5):521-4. [PMID: 15491376]">BenâZeev 2004</a>; <a href="./references#CD010062-bbs2-0016" title="ChahemJ , BauerJ . Treatment of epilepsy with third-line antiepileptic drugs: felbamate, tiagabine and sulthiame. Der Nervenarzt2007;78(12):1407-12. [PMID: 17604973]">Chahem 2007</a>). Pharmacological treatment remains the first choice for controlling epilepsy, although recent decades have seen advances in vagal stimulation, <a href="./references#CD010062-bbs2-0030" title="PanebiancoM , RigbyA , WestonJ , MarsonAG . Vagus nerve stimulation for partial seizures. Cochrane Database of Systematic Reviews2015, Issue 4. Art. No: CD002896. [DOI: 10.1002/14651858.CD002896.pub2]">Panebianco 2015</a>; <a href="./references#CD010062-bbs2-0031" title="PanebiancoM , ZavanoneC , DupontS , RestivoDA , PavoneA . Vagus nerve stimulation therapy in partial epilepsy: a review. Acta Neurologica Belgica2016;116(3):241-8. [PMID: 26908034]">Panebianco 2016</a>, and surgery (<a href="./references#CD010062-bbs2-0039" title="WestS , NevittSJ , CottonJ , GandhiS , WestonJ , SudanA , et al. Surgery for epilepsy. Cochrane Database of Systematic Reviews2019, Issue 6. Art. No: CD010541. [DOI: 10.1002/14651858.CD010541.pub3]">West 2019</a>). </p> <p>When used as monotherapy, STM has been reported to reduce the occurrence of seizures and electroencephalographic (EEG) discharges in study participants with benign epilepsy of childhood with centrotemporal spikes (BECTS) (<a href="./references#CD010062-bbs2-0033" title="RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6-month randomized, double-blind, placebo-controlled study. Sulthiame Study Group. Epilepsia2000;41(10):1284-8. [PMID: 11051123]">Rating 2000</a>; <a href="./references#CD010062-bbs2-0012" title="BastT , VolpA , WolfC , RatingD , Sulthiame Study Group. The influence of sulthiame on EEG in children with benign childhood epilepsy with centrotemporal spikes (BECTS). Epilepsia2003;44(2):215-20. [PMID: 12558577]">Bast 2003</a>; <a href="./references#CD010062-bbs2-0013" title="Ben-ZeevB , WatembergN , LermanP , BarashI , BrandN , Lerman-SagieT . Sulthiame in childhood epilepsy. Paediatrics International2004;46(5):521-4. [PMID: 15491376]">BenâZeev 2004</a>; <a href="./references#CD010062-bbs2-0042" title="WirrellE , ShermanEMS , VanmastrigtR , HamiwkaL . Deterioration in cognitive function in children with benign epilepsy of childhood with central temporal spikes treated with sulthiame. Journal of Child Neurology2008;23(1):14-21. [PMID: 18184938]">Wirrell 2008</a>), benign partial epilepsy of childhood (<a href="./references#CD010062-bbs2-0018" title="EnglerF , Maeder-IngvarM , RouletE , DeonnaT . Treatment with sulthiame (ospolot) in benign partial epilepsy of childhood and related syndromes: an open clinical and EEG study. Neuropediatrics2003;34(2):105-9. [PMID: 12776234]">Engler 2003</a>; <a href="./references#CD010062-bbs2-0013" title="Ben-ZeevB , WatembergN , LermanP , BarashI , BrandN , Lerman-SagieT . Sulthiame in childhood epilepsy. Paediatrics International2004;46(5):521-4. [PMID: 15491376]">BenâZeev 2004</a>), symptomatic, localisationârelated epilepsy and juvenile myoclonic epilepsy (<a href="./references#CD010062-bbs2-0013" title="Ben-ZeevB , WatembergN , LermanP , BarashI , BrandN , Lerman-SagieT . Sulthiame in childhood epilepsy. Paediatrics International2004;46(5):521-4. [PMID: 15491376]">BenâZeev 2004</a>), as well as adults with drugâresistant epilepsy and learning disabilities (<a href="./references#CD010062-bbs2-0026" title="KoeppMJ , PatsalosPN , SanderJWAS . Sulthiame in adults with refractory epilepsy and learning disability: an open trial. Epilepsy Research2002;50(3):277-82. [PMID: 12200218]">Koepp 2002</a>). In addition, STM as an addâon therapy has been reported to reduce seizure activity in participants with drugâresistant epilepsy (<a href="./references#CD010062-bbs2-0010" title="LivingstonS , VillamaterC , SakataY . Ospolot (sulthiame) in epilepsy. Diseases of the Nervous System1967;28(4):259-63. [PMID: 4381572]">Livingston 1967</a>; <a href="./references#CD010062-bbs2-0016" title="ChahemJ , BauerJ . Treatment of epilepsy with third-line antiepileptic drugs: felbamate, tiagabine and sulthiame. Der Nervenarzt2007;78(12):1407-12. [PMID: 17604973]">Chahem 2007</a>; <a href="./references#CD010062-bbs2-0029" title="MiyajimaT , KumadaT , KimuraN , MikuniT , FujiiT . Sulthiame treatment for patients with intractable epilepsy. No To Hattatsu2009;41(1):17-20. [DOI: 10.11251/ojjscn.41.17]">Miyajima 2009</a>). Reported adverse effects of STM include deterioration of reading ability, memory, attention skills, and mathematical ability (<a href="./references#CD010062-bbs2-0042" title="WirrellE , ShermanEMS , VanmastrigtR , HamiwkaL . Deterioration in cognitive function in children with benign epilepsy of childhood with central temporal spikes treated with sulthiame. Journal of Child Neurology2008;23(1):14-21. [PMID: 18184938]">Wirrell 2008</a>), mixed respiratory and metabolic acidosis (<a href="./references#CD010062-bbs2-0038" title="WeissbachA , TiroshI , ScheuermanO , HofferV , GartyBZ . Respiratory alkalosis and metabolic acidosis in a child treated with sulthiame. Pediatric Emergency Care2010;26(10):752-3. [PMID: 20930598]">Weissbach 2010</a>), and crystalluria (<a href="./references#CD010062-bbs2-0019" title="GoT . Effect of antiepileptic drug polytherapy on crystalluria. Pediatric Neurology2005;32(2):113-5. [PMID: 15664771]">Go 2005</a>). </p> </section> <section id="CD010062-sec-0012"> <h3 class="title" id="CD010062-sec-0012">How the intervention might work</h3> <p>At the time of the writing of this review, no studies have systematically reviewed the literature on the mechanism of action of STM. Early studies suggest that the main antiepileptic properties of STM are indirect and due to a pharmacokinetic interaction with phenytoin (PHT): by inhibiting the parahydroxylation of phenytoin by hepatic enzymes, STM increases the serum levels and halfâlife of PHT when taken in combination (<a href="./references#CD010062-bbs2-0023" title="HoughtonGW , RichensA . Inhibition of phenytoin metabolism by sulthiame in epileptic patients. British Journal of Clinical Pharmacology1974;1(1):59â66. [PMID: 22454870]">Houghton 1974</a>). More recent studies have found that STM produces a modest intracellular acidosis in central neurons via its action as a carbonic anhydrase inhibitor, thereby reducing the frequency of action potentials and epileptiform bursts (<a href="./references#CD010062-bbs2-0028" title="LenigerT , WiemannM , BingmannD , WidmanG , HufnagelA , BonnetU . Carbonic anhydrase inhibitor sulthiame reduces intracellular pH and epileptiform activity of hippocampal CA3 neurons. Epilepsia2002;43(5):469-74. [PMID: 12027906]">Leniger 2002</a>). </p> </section> <section id="CD010062-sec-0013"> <h3 class="title" id="CD010062-sec-0013">Why it is important to do this review</h3> <p>This review, which is an update of a previous Cochrane Review (<a href="./references#CD010062-bbs2-0044" title="Milburn-McNultyP , PowellG , SillsGJ , MarsonAG . Sulthiame monotherapy for epilepsy. Cochrane Database of Systematic Reviews2014, Issue 3. Art. No: CD010062. [DOI: 10.1002/14651858.CD010062.pub2]">MilburnâMcNulty 2014</a>), aims to summarise evidence from randomised controlled trials where the efficacy and tolerability of STM in monotherapy for participants with epilepsy has been investigated, in order to inform the use of this drug and decisions about its further assessment. A separate Cochrane Review has addressed the use of STM as an addâon treatment (<a href="./references#CD010062-bbs2-0014" title="BresnahanR , MartinâMcGillKJ , MilburnâMcNultyP , PowellG , SillsGJ , MarsonAG . Sulthiame add-on therapy for epilepsy. Cochrane Database of Systematic Reviews2019, Issue 8. Art. No: CD009472. [DOI: 10.1002/14651858.CD009472.pub4]">Bresnahan 2019</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010062-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010062-sec-0014"></div> <p>To assess the efficacy and side effect profile of STM as monotherapy when compared with placebo or another antiepileptic drug for people with epilepsy. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010062-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010062-sec-0015"></div> <section id="CD010062-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010062-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included trials that met all of the following criteria.</p> <p> <ul id="CD010062-list-0001"> <li> <p>Randomised controlled trials, in which an adequate method of concealment of randomisation was used (e.g. allocation of sequentially sealed packages of medication; sealed, opaque envelopes; telephone randomisation). </p> </li> <li> <p>Doubleâblinded, singleâblinded, or unblinded trials.</p> </li> <li> <p>Placeboâcontrolled or actively controlled trials.</p> </li> <li> <p>Parallelâgroup and crossâover studies. For crossâover studies, we treated the first treatment period as a parallel trial, for the purposes of analysis of efficacy and safety data (i.e. only data from the first treatment period were used). </p> </li> </ul> </p> </section> <section id="CD010062-sec-0018"> <h4 class="title">Types of participants</h4> <p> <ul id="CD010062-list-0002"> <li> <p>Individuals with epilepsy of any aetiology.</p> </li> <li> <p>Persons of any age.</p> </li> </ul> </p> </section> <section id="CD010062-sec-0019"> <h4 class="title">Types of interventions</h4> <p> <ul id="CD010062-list-0003"> <li> <p>For the active intervention group, STM taken as monotherapy.</p> </li> <li> <p>For the control group, placebo or another AED taken as monotherapy.</p> </li> </ul> </p> </section> <section id="CD010062-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD010062-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD010062-list-0004"> <li> <p><b>Treatment withdrawal.</b> We chose the proportion of participants who had treatment withdrawn during the course of the treatment period as a measure of global effectiveness. This outcome reflects both efficacy and tolerability, as treatment may be withdrawn because of continued seizures, adverse effects, or a combination of both. This outcome is recommended by the Commission on Antiepileptic Drugs of the International League Against Epilepsy as the primary outcome measure in monotherapy trials (<a href="./references#CD010062-bbs2-0017" title="Commission on Antiepileptic Drugs. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia1998;39(7):799-803. [PMID: 9670910]">Commission on Antiepileptic Drugs 1998</a>). </p> </li> </ul> </p> </section> <section id="CD010062-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD010062-list-0005"> <li> <p><b>Seizure freedom.</b> The proportion of people with complete cessation of seizures during the treatment period. </p> </li> <li> <p><b>Adverse effects.</b> Any reported adverse effects such as, but not limited to, deterioration in cognitive ability, crystalluria, or respiratory and metabolic acidosis. We will assess both the proportion of any adverse effect and the proportion of each individual adverse effect. </p> </li> <li> <p><b>Quality of life (QoL).</b> Overall improvement or deterioration in QoL as assessed by validated and reliable rating scales. </p> </li> </ul> </p> </section> </section> </section> <section id="CD010062-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010062-sec-0024"> <h4 class="title">Electronic searches</h4> <p>Searches were run for the original review on 28 August 2012. Subsequent searches were run on 24 October 2014, 7 March 2018, and 12 September 2017. For the latest update, we searched the following databases on 13 April 2020. </p> <p> <ul id="CD010062-list-0006"> <li> <p>Cochrane Register of Studies (CRS Web) using the search strategy shown in <a href="./appendices#CD010062-sec-0087">Appendix 1</a>. </p> </li> <li> <p>MEDLINE (Ovid, 1946 to 10 April 2020) using the search strategy shown in <a href="./appendices#CD010062-sec-0088">Appendix 2</a>. </p> </li> </ul> </p> <p>We imposed no language restrictions.</p> <p>CRS Web includes randomised or quasiârandomised controlled trials from PubMed, Embase, US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov, the World Health Organization International Clinical Trials Registry Platform, the Cochrane Central Register of Controlled Trials (CENTRAL), and the specialised registers of Cochrane Review Groups including Cochrane Epilepsy. We previously searched Scopus as a substitute for Embase, using the search strategy shown in <a href="./appendices#CD010062-sec-0089">Appendix 3</a>, but because of CRS Web, this was no longer necessary. </p> </section> <section id="CD010062-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of retrieved reports for additional reports of relevant studies, including conference proceedings. We contacted the manufacturers of STM and colleagues in the field to ask for information about ongoing or unpublished studies. </p> </section> </section> <section id="CD010062-sec-0026"> <h3 class="title" id="CD010062-sec-0026">Data collection and analysis</h3> <section id="CD010062-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (PMâM and MP) independently assessed studies for inclusion. Any disagreements were resolved by discussion or through arbitration with the third review author (AGM) if necessary. Two review authors (PMâM and MP) independently extracted data from and assessed risk of bias of the included trials, with any disagreements resolved by discussion. </p> </section> <section id="CD010062-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (PMâM and MP) independently extracted data from the included trials and assessed study design and demographic makeup of the participants, in addition to the outcomes listed in the <a href="#CD010062-sec-0020">Types of outcome measures</a> section. All outcome measure data were separated into intervention group and control group data. Any disagreements were resolved by discussion or through arbitration with the third review author (AGM) if necessary. </p> <section id="CD010062-sec-0029"> <h5 class="title">Methods and trial design</h5> <p> <ul id="CD010062-list-0007"> <li> <p>Method of randomisation.</p> </li> <li> <p>Method of allocation concealment.</p> </li> <li> <p>Method of blinding.</p> </li> <li> <p>Crossâover or parallel trial.</p> </li> <li> <p>Duration of study.</p> </li> <li> <p>Duration of baseline period.</p> </li> <li> <p>Duration of treatment period.</p> </li> <li> <p>Duration of 'washout' period for crossâover studies.</p> </li> <li> <p>Dose of STM.</p> </li> <li> <p>Description of how adverse effects were reported.</p> </li> <li> <p>Source of funding.</p> </li> </ul> </p> </section> <section id="CD010062-sec-0030"> <h5 class="title">Participants and demographic information</h5> <p> <ul id="CD010062-list-0008"> <li> <p>Number of participants in the intervention group.</p> </li> <li> <p>Number of participants in the control group.</p> </li> <li> <p>Study setting.</p> </li> <li> <p>Country in which study was performed.</p> </li> <li> <p>Age.</p> </li> <li> <p>Sex.</p> </li> <li> <p>Ethnicity.</p> </li> <li> <p>Whether treatmentânaive (i.e. has the participant taken any AEDs previously, and if so, which ones?). </p> </li> <li> <p>Diagnostic criteria.</p> </li> <li> <p>Types of seizures and epilepsy.</p> </li> <li> <p>Number of seizures before the start of treatment.</p> </li> </ul> </p> </section> <section id="CD010062-sec-0031"> <h5 class="title">Outcomes</h5> <p> <ul id="CD010062-list-0009"> <li> <p>Time to treatment failure: number of events, time to treatment failure, and reason for treatment failure. </p> </li> <li> <p>Time to 12âmonth remission: number of events and time to 12âmonth remission.</p> </li> <li> <p>Proportion seizureâfree at 12 months: number of events.</p> </li> <li> <p>Adverse effects: number of events, and categorisation into specific adverse effects.</p> </li> <li> <p>Overall improvement or deterioration in quality of life: type of scale used, score before and after intervention, and time postintervention quality of life scoring repeated. </p> </li> </ul> </p> <p>See <a href="#CD010062-sec-0020">Types of outcome measures</a>. </p> </section> </section> <section id="CD010062-sec-0032"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (PMâM and MP) independently assessed the risk of bias for each trial using the Cochrane risk of bias tool as described in the <i>Cochrane Handbook for Systematic Review of Interventions</i> (<a href="./references#CD010062-bbs2-0022" title="HigginsJPT , AltmanDG , SterneJAC , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). Any disagreements were resolved by discussion or through arbitration with the third review author (AGM) if necessary. We completed a risk of bias table for each included study in Review Manager 5 (<a href="./references#CD010062-bbs2-0034" title="Review Manager (RevMan). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We rated each included study as having a low, high, or unclear risk of bias on several domains applicable to randomised controlled trials, as follows. </p> <p> <ul id="CD010062-list-0010"> <li> <p>Random sequence generation (selection bias).</p> </li> <li> <p>Allocation concealment (selection bias).</p> </li> <li> <p>Blinding of participants and personnel (performance bias).</p> </li> <li> <p>Blinding of outcome assessment (detection bias).</p> </li> <li> <p>Incomplete outcome data (attrition bias).</p> </li> <li> <p>Selective outcome reporting (reporting bias).</p> </li> <li> <p>Other sources of bias.</p> </li> </ul> </p> </section> <section id="CD010062-sec-0033"> <h4 class="title">Measures of treatment effect</h4> <p>We expressed dichotomous data as risk ratios (RRs) with 95% confidence intervals (CIs), and planned to express timeâtoâevent outcomes as hazard ratios (HRs) with 95% CIs. We planned that if HRs were not reported directly, we would use previously reported methods to approximate these values (<a href="./references#CD010062-bbs2-0032" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815-34. [PMID: 9921604]">Parmar 1998</a>; <a href="./references#CD010062-bbs2-0041" title="WilliamsonPR , SmithCT , HuttonJL , MarsonAG . Aggregate data meta-analysis with time to event outcomes. Statistics in Medicine2002;21(22):3337-51. [PMID: 12407676]">Williamson 2002</a>). For quality of life data, we planned to use mean differences (MDs) with 95% CIs. </p> </section> <section id="CD010062-sec-0034"> <h4 class="title">Unit of analysis issues</h4> <p>We analysed parallelâarm and crossâover design studies in separate subgroups.</p> </section> <section id="CD010062-sec-0035"> <h4 class="title">Dealing with missing data</h4> <p>We planned to implement an intentionâtoâtreat analysis for all primary and secondary outcomes. We planned to calculate any missing statistics from the raw data when possible. </p> </section> <section id="CD010062-sec-0036"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to assess methodological heterogeneity by comparing trials based on the items outlined in the Methods and trial design section in <a href="#CD010062-sec-0028">Data extraction and management</a>, and to assess clinical heterogeneity by comparing trials based on the items outlined in the Participants and demographic information section in <a href="#CD010062-sec-0028">Data extraction and management</a>. If we found a forest plot to be appropriate, we would perform a visual inspection to identify any inconsistencies amongst studies and quantify this using the I<sup>2</sup> statistic, using the following parameters as a guide. </p> <p> <ul id="CD010062-list-0011"> <li> <p>0% to 40%: might not be important.</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity.</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity.</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> </section> <section id="CD010062-sec-0037"> <h4 class="title">Assessment of reporting biases</h4> <p>We requested protocols for all of the included studies to enable a comparison of our outcomes of interest. In the case of sufficient randomised controlled trials, we would prepare a funnel plot to help identify publication bias, further investigating any visual asymmetry by exploratory analysis. We attempted to obtain source data for all studies included in the analysis to assess any nonâreported outcomes. We investigated outcome reporting bias using the Outcome Reporting Bias In Trials (ORBIT) matrix system for benefit outcomes (<a href="./references#CD010062-bbs2-0025" title="KirkhamJJ , DwanKM , AltmanDG , GambleC , DoddS , SmythR , et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ2010;340:c365. [DOI: 10.1136/bmj.c365] [PMID: 20156912]">Kirkham 2010</a>). </p> </section> <section id="CD010062-sec-0038"> <h4 class="title">Data synthesis</h4> <p>We planned to analyse data in a metaâanalysis using a fixedâeffect model within Review Manager 5 (<a href="./references#CD010062-bbs2-0034" title="Review Manager (RevMan). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>), provided this was clinically appropriate and there was no evidence of substantial heterogeneity. If we found evidence of substantial heterogeneity, we would explore the factors for heterogeneity; if substantial heterogeneity could not be readily explained, we would use a randomâeffects model to perform metaâanalysis. Our primary analysis was intentionâtoâtreat, in which all participants are included in the intervention groups to which they have been allocated, irrespective of whether they had received the treatment. We analysed data as set out in <a href="#CD010062-sec-0033">Measures of treatment effect</a>. We analysed different control groups separately. A P value of less than 0.05 qualified statistical significance. </p> <p>We did not undertake metaâanalysis in this review update as no more than one study was combined together. A narrative analysis of the data is presented. </p> </section> <section id="CD010062-sec-0039"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to separately assess the effects of STM in participants with focal epilepsy and in those with generalised epilepsy. We planned to separately assess the effects of different doses of STM. Given the small number of included studies, we were unable to conduct any meaningful subgroup analysis. </p> </section> <section id="CD010062-sec-0040"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to conduct the following sensitivity analyses to test the robustness of the metaâanalysis, where possible. </p> <p> <ul id="CD010062-list-0012"> <li> <p>Repeating the analysis with exclusion of unpublished studies.</p> </li> <li> <p>Repeating the analysis with exclusion of studies published only as abstracts.</p> </li> </ul> </p> <p>These sensitivity analyses were not required to be conducted in the current review, as all included studies were published journal articles. </p> </section> <section id="CD010062-sec-0041"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created summary of findings tables using <a href="./references#CD010062-bbs2-0020" title="GRADEpro GDT [GRADEpro Guideline Development Tool [Software]]. McMaster University, 2020 (developed by Evidence Prime, Inc.), 2020. Available from gradepro.org.">GRADEpro GDT</a> software, and employed the GRADE approach to assess the certainty of evidence for the following outcomes: treatment withdrawal, seizure freedom, and adverse effects (<a href="./references#CD010062-bbs2-0037" title="SchÃ¼nemannH , BroÅ¼ekJ , GuyattG , OxmanA , editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.">SchÃ¼nemann 2013</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010062-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010062-sec-0042"></div> <section id="CD010062-sec-0043"> <h3 class="title">Description of studies</h3> <section id="CD010062-sec-0044"> <h4 class="title">Results of the search</h4> <p>The electronic searches identified a total of 170 references (<a href="#CD010062-fig-0001">Figure 1</a>). After the removal of duplicates and irrelevant records, we screened the remaining 18 records, identifying 8 potentially eligible studies. After screening the fullâtext publications for these 8 studies, we included one study (<a href="./references#CD010062-sec-0099" title="">Characteristics of included studies</a>), and excluded 7 studies (<a href="./references#CD010062-sec-0100" title="">Characteristics of excluded studies</a>). </p> <div class="figure" id="CD010062-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD010062-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD010062-sec-0045"> <h4 class="title">Included studies</h4> <p>We included one additional study in this update (<a href="./references#CD010062-bbs2-0002" title="BorggraefeI , BonfertM , BastT , NeubauerBA , SchottenKJ , MassmannK , et al. Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study). European Journal of Paediatric Neurology2013;17(5):507-14. [DOI: 10.1016/j.ejpn.2013.03.014] [PMID: 23642492]BorggraefeI , BonfertM , GerstlL , HeinenF , NeubauerB . A double-blinded, randomized evaluation of neuropsychological and behavioral changes in children with benign epilepsy with centrotemporal spikes treated either with levetiracetam or sulthiame. Epilepsy Currents2015;15(Suppl 1):278, Abstract no: 2.04. TackeM , BorggraefeI , GerstlL , HeinenF , VillK , BonfertM , et al. Effects of levetiracetam and sulthiame on EEG in benign epilepsy with centrotemporal spikes: a randomized controlled trial. Seizure2018;56:115-20. [DOI: 10.1016/j.seizure.2018.01.015] [PMID: 29475094]TackeM , GerstlL , HeinenF , HeukaeuferI , BonfertM , BastT , et al. Effect of anticonvulsive treatment on neuropsychological performance in children with BECTS. European Journal of Paediatric Neurology2016;20(6):874-9. [DOI: 10.1016/j.ejpn.2016.07.015] [PMID: 27553576]TackeM . EEG changes in rolandic epilepsy under treatment with levetiracetam and sulthiame. European Journal of Paediatric Neurology2017;21(Suppl 1):e97, Abstract no: P2-5. [DOI: 10.1016/j.ejpn.2017.04.733]">Borggraefe 2013</a>; 43 participants). A total of four studies met our inclusion criteria (<a href="./references#CD010062-bbs2-0004" title='BastT , VÃ¶lpA , WolfC , RatingD . The influence of sulthiame on EEG in children with benign epilepsy with centrotemporal spikes (BECTS). Epilepsia2003;44(2):215-20. [PMID: 12558577]RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6-month randomized, double-blind, placebo-controlled study. Epilepsia2000;41(10):1284-8. [PMID: 11051123]RatingD , WolfC . Sulthiame vs placebo in the treatment of benign epilepsy with centrotemporal spikes ("rolandic" epilepsy). Epilepsia1999;40(Suppl 2):163. '>Rating 1999</a>; <a href="./references#CD010062-bbs2-0003" title="Li Jimin, Li Zuohan, Jin Yongqing, Pan Daoming, Xu Peixi, Hu Dameng, Xu Min. A randomized controlled multicenter clinical study on sulthiame in the treatment of GTCS. Journal of Clinical Neurology2000;13(6):345-7. ">Li 2000</a>; <a href="./references#CD010062-bbs2-0001" title="BasnecA , SkarpaD , BarisicN , JurinM , Mucic-PucicB . The risk of second seizure in children with benign childhood epilepsy with centrotemporal spikes without treatment - a prospective study [Rizik javljanja drugog napadaja u nelijeÄene djece s benignom parcijalnom epilepsijom s centrotemporalnim Å¡iljaka - prospektivno istraÅ¾ivanje]. Acta Medica Croatica2005;59(1):59-62. [PMID: 15813357]">Basnec 2005</a>; <a href="./references#CD010062-bbs2-0002" title="BorggraefeI , BonfertM , BastT , NeubauerBA , SchottenKJ , MassmannK , et al. Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study). European Journal of Paediatric Neurology2013;17(5):507-14. [DOI: 10.1016/j.ejpn.2013.03.014] [PMID: 23642492]BorggraefeI , BonfertM , GerstlL , HeinenF , NeubauerB . A double-blinded, randomized evaluation of neuropsychological and behavioral changes in children with benign epilepsy with centrotemporal spikes treated either with levetiracetam or sulthiame. Epilepsy Currents2015;15(Suppl 1):278, Abstract no: 2.04. TackeM , BorggraefeI , GerstlL , HeinenF , VillK , BonfertM , et al. Effects of levetiracetam and sulthiame on EEG in benign epilepsy with centrotemporal spikes: a randomized controlled trial. Seizure2018;56:115-20. [DOI: 10.1016/j.seizure.2018.01.015] [PMID: 29475094]TackeM , GerstlL , HeinenF , HeukaeuferI , BonfertM , BastT , et al. Effect of anticonvulsive treatment on neuropsychological performance in children with BECTS. European Journal of Paediatric Neurology2016;20(6):874-9. [DOI: 10.1016/j.ejpn.2016.07.015] [PMID: 27553576]TackeM . EEG changes in rolandic epilepsy under treatment with levetiracetam and sulthiame. European Journal of Paediatric Neurology2017;21(Suppl 1):e97, Abstract no: P2-5. [DOI: 10.1016/j.ejpn.2017.04.733]">Borggraefe 2013</a>), comprising 355 participants. One study, <a href="./references#CD010062-bbs2-0004" title='BastT , VÃ¶lpA , WolfC , RatingD . The influence of sulthiame on EEG in children with benign epilepsy with centrotemporal spikes (BECTS). Epilepsia2003;44(2):215-20. [PMID: 12558577]RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6-month randomized, double-blind, placebo-controlled study. Epilepsia2000;41(10):1284-8. [PMID: 11051123]RatingD , WolfC . Sulthiame vs placebo in the treatment of benign epilepsy with centrotemporal spikes ("rolandic" epilepsy). Epilepsia1999;40(Suppl 2):163. '>Rating 1999</a>, accounted for two of the search results: <a href="./references#CD010062-bbs2-0004" title='BastT , VÃ¶lpA , WolfC , RatingD . The influence of sulthiame on EEG in children with benign epilepsy with centrotemporal spikes (BECTS). Epilepsia2003;44(2):215-20. [PMID: 12558577]RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6-month randomized, double-blind, placebo-controlled study. Epilepsia2000;41(10):1284-8. [PMID: 11051123]RatingD , WolfC . Sulthiame vs placebo in the treatment of benign epilepsy with centrotemporal spikes ("rolandic" epilepsy). Epilepsia1999;40(Suppl 2):163. '>Rating 1999</a> and <a href="./references#CD010062-bbs2-0033" title="RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6-month randomized, double-blind, placebo-controlled study. Sulthiame Study Group. Epilepsia2000;41(10):1284-8. [PMID: 11051123]">Rating 2000</a>; each publication reported data for the same study. Four additional references (Borggraefe 2015; Tracke 2016; Tracke 2017; Tracke 2018) relate to a new study (<a href="./references#CD010062-bbs2-0002" title="BorggraefeI , BonfertM , BastT , NeubauerBA , SchottenKJ , MassmannK , et al. Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study). European Journal of Paediatric Neurology2013;17(5):507-14. [DOI: 10.1016/j.ejpn.2013.03.014] [PMID: 23642492]BorggraefeI , BonfertM , GerstlL , HeinenF , NeubauerB . A double-blinded, randomized evaluation of neuropsychological and behavioral changes in children with benign epilepsy with centrotemporal spikes treated either with levetiracetam or sulthiame. Epilepsy Currents2015;15(Suppl 1):278, Abstract no: 2.04. TackeM , BorggraefeI , GerstlL , HeinenF , VillK , BonfertM , et al. Effects of levetiracetam and sulthiame on EEG in benign epilepsy with centrotemporal spikes: a randomized controlled trial. Seizure2018;56:115-20. [DOI: 10.1016/j.seizure.2018.01.015] [PMID: 29475094]TackeM , GerstlL , HeinenF , HeukaeuferI , BonfertM , BastT , et al. Effect of anticonvulsive treatment on neuropsychological performance in children with BECTS. European Journal of Paediatric Neurology2016;20(6):874-9. [DOI: 10.1016/j.ejpn.2016.07.015] [PMID: 27553576]TackeM . EEG changes in rolandic epilepsy under treatment with levetiracetam and sulthiame. European Journal of Paediatric Neurology2017;21(Suppl 1):e97, Abstract no: P2-5. [DOI: 10.1016/j.ejpn.2017.04.733]">Borggraefe 2013</a>). </p> <p><a href="./references#CD010062-bbs2-0004" title='BastT , VÃ¶lpA , WolfC , RatingD . The influence of sulthiame on EEG in children with benign epilepsy with centrotemporal spikes (BECTS). Epilepsia2003;44(2):215-20. [PMID: 12558577]RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6-month randomized, double-blind, placebo-controlled study. Epilepsia2000;41(10):1284-8. [PMID: 11051123]RatingD , WolfC . Sulthiame vs placebo in the treatment of benign epilepsy with centrotemporal spikes ("rolandic" epilepsy). Epilepsia1999;40(Suppl 2):163. '>Rating 1999</a> was a multicentre, randomised, doubleâblind, placeboâcontrolled, parallelâgroup study. Children between the ages of three and 10 years, weighing between 10 and 50 kg and with a diagnosis of BECTS with at least two seizures in the past six months, were recruited into the study. Children with severe organic disease, acute porphyria, a history of mental illness, relevant hypersensitivity reactions, relevant renal, thyroid, or hepatic dysfunction, and somatic signs of puberty or AED treatment after the age of six months (unless treatment was provided for less than six months) were excluded. A total of 66 participants were randomly assigned: 31 participants received STM, and 35 received placebo. Participants in the intervention group had a median (range) age of 8.2 years (3.9 to 10.7 years); participants in the placebo group had a median (range) age of 8.4 years (3.1 to 10.3 years). Interquartile age was not reported. There were 16 (52%) males and 15 (48%) females in the intervention group and 24 (69%) males and 11 (31%) females in the control group. After a sixâmonth historic baseline period, during which participants kept a seizure diary but received no intervention or placebo, participants were randomly assigned to receive STM (5 mg/kg/d) or placebo during a sixâmonth treatment phase. No titration period was provided. Seizure activity was recorded by participants in a diary, and assessments occurred at screening, on day 14, on day 28, after three months, and at the end of the sixâmonth treatment phase. On day 14, assessment consisted of physical and neurological examinations, review of seizure diaries, and evaluation of adverse effects, intercurrent illnesses, and medications. During subsequent reviews, assessment included laboratory tests such as STM plasma levels and awake and asleep EEG changes. </p> <p><a href="./references#CD010062-bbs2-0003" title="Li Jimin, Li Zuohan, Jin Yongqing, Pan Daoming, Xu Peixi, Hu Dameng, Xu Min. A randomized controlled multicenter clinical study on sulthiame in the treatment of GTCS. Journal of Clinical Neurology2000;13(6):345-7. ">Li 2000</a> was a multicentre, randomised, doubleâblind, activeâcontrolled (phenytoin (PHT)), parallelâgroup study in which an additional third group received STM openly. Individuals with generalised tonicâclonic seizures (GTCS) who had experienced a seizure within three to six months of the study start date were recruited into the study. Participants in the intervention group had a mean (standard deviation (SD)) age of 29.53 (15.09) years; participants in the placebo group had a mean (SD) age of 34.91 (15.12) years. Participants in the open group had a mean (SD) age of 27.69 (16.76) years. Thirtyâtwo participants in the intervention group received STM, and 32 participants in the control group received PHT; a further 82 participants in the open group received STM. The intervention group included 18 (56%) males and 14 (44%) females. The treatment phase lasted for six months; however, no information was provided on loading or titration periods, or whether a historic baseline period was included. The control group included 17 (53%) males and 15 (47%) females. The open group included 57 (70%) males and 25 (30%) females. At the start of the trial, participants were randomly assigned to receive STM (100 to 200 mg/d) or PHT (300 mg/d) as a doubleâblind treatment, or STM (100 to 200 mg/d) as an open treatment. Treatment continued for six months, during which seizure frequency and adverse effects were measured on a monthly basis. Laboratory tests consisting of blood count, liver function, kidney function, electrocardiogram (ECG), and EEG were carried out before treatment commenced and after the sixâmonth treatment period had been completed. </p> <p>Providing a robust analysis of <a href="./references#CD010062-bbs2-0001" title="BasnecA , SkarpaD , BarisicN , JurinM , Mucic-PucicB . The risk of second seizure in children with benign childhood epilepsy with centrotemporal spikes without treatment - a prospective study [Rizik javljanja drugog napadaja u nelijeÄene djece s benignom parcijalnom epilepsijom s centrotemporalnim Å¡iljaka - prospektivno istraÅ¾ivanje]. Acta Medica Croatica2005;59(1):59-62. [PMID: 15813357]">Basnec 2005</a>, which was published in Croatian, is difficult because of the lack of a reliable English translation of the full text. We will aim to obtain an English translation of the full text in future updates of this review and will discuss below information that could be obtained from the English translation of the abstract. <a href="./references#CD010062-bbs2-0001" title="BasnecA , SkarpaD , BarisicN , JurinM , Mucic-PucicB . The risk of second seizure in children with benign childhood epilepsy with centrotemporal spikes without treatment - a prospective study [Rizik javljanja drugog napadaja u nelijeÄene djece s benignom parcijalnom epilepsijom s centrotemporalnim Å¡iljaka - prospektivno istraÅ¾ivanje]. Acta Medica Croatica2005;59(1):59-62. [PMID: 15813357]">Basnec 2005</a> was a multicentre, randomised, doubleâblind, placeboâcontrolled, parallelâgroup study. Details on dosing and study phases were not provided. 34 participants were randomly assigned. Children between the ages of three and 11 years who had experienced a single seizure only and had received no AED treatment were recruited into the study. Participants received STM or placebo, and data were collected on the proportion of participants who withdrew from treatment; proportion of participants who experienced a second seizure within six months; proportion of participants who experienced a second seizure after six months; and proportion of participants who experienced status epilepticus. </p> <p><a href="./references#CD010062-bbs2-0002" title="BorggraefeI , BonfertM , BastT , NeubauerBA , SchottenKJ , MassmannK , et al. Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study). European Journal of Paediatric Neurology2013;17(5):507-14. [DOI: 10.1016/j.ejpn.2013.03.014] [PMID: 23642492]BorggraefeI , BonfertM , GerstlL , HeinenF , NeubauerB . A double-blinded, randomized evaluation of neuropsychological and behavioral changes in children with benign epilepsy with centrotemporal spikes treated either with levetiracetam or sulthiame. Epilepsy Currents2015;15(Suppl 1):278, Abstract no: 2.04. TackeM , BorggraefeI , GerstlL , HeinenF , VillK , BonfertM , et al. Effects of levetiracetam and sulthiame on EEG in benign epilepsy with centrotemporal spikes: a randomized controlled trial. Seizure2018;56:115-20. [DOI: 10.1016/j.seizure.2018.01.015] [PMID: 29475094]TackeM , GerstlL , HeinenF , HeukaeuferI , BonfertM , BastT , et al. Effect of anticonvulsive treatment on neuropsychological performance in children with BECTS. European Journal of Paediatric Neurology2016;20(6):874-9. [DOI: 10.1016/j.ejpn.2016.07.015] [PMID: 27553576]TackeM . EEG changes in rolandic epilepsy under treatment with levetiracetam and sulthiame. European Journal of Paediatric Neurology2017;21(Suppl 1):e97, Abstract no: P2-5. [DOI: 10.1016/j.ejpn.2017.04.733]">Borggraefe 2013</a> was a multicentre (from 47 German centres), prospective, doubleâblinded, randomised controlled trial, conducted over a period of 26 months. Children between six and 12 years of age with a body weight of between 19 and 45 kg, with a diagnosis of BECTS, who had experienced two or more seizures in the past six months were recruited into the study. A total of 44 participants were randomly assigned to STM (6 mg/kg bodyweight) or levetiracetam (LEV) (30 mg/kg bodyweight) treatment group. Fortyâthree participants were analysed (one participant was excluded due to a protocol violation). Children with LandauâKleffner syndrome and epileptic encephalopathy with continuous spike and wave during sleep, and relevant medical conditions (i.e. hepatopathy, nephropathy, disorders of the heart, endocrine system, and metabolic diseases) were excluded. Participants in the intervention group had a mean (SD) age of 9 years (1.5); participants in the control group had a mean (SD) age of 8.7 years (1.7). A total of 22 participants received STM, and 21 received LEV. The intervention group included 12 (54.5%) males and 10 (45.5%) females; the control group included 15 (71.4%) males and 6 (28.6%) females. Medication was started at a dosage of 2 mg/kg bodyweight (STM) or 10 mg/kg bodyweight (LEV), and was increased weekly by increments of 2 and 10 mg/kg bodyweight weekly to a final dosage of 6 and 30 mg/kg bodyweight, respectively. After a total observation period of 24 weeks whilst children took the recommended study dosage, the study was unblinded, and the local principal investigator and participants could choose to continue the treatment or not. Explorative data analysis was performed to investigate the number of total dropouts, participants who experienced seizure freedom, and occurrence of adverse events. </p> </section> <section id="CD010062-sec-0046"> <h4 class="title">Excluded studies</h4> <p>Three studies administered STM to participants with epilepsy but did not include a placebo group (not randomised controlled trials) (<a href="./references#CD010062-bbs2-0008" title="IngramTT , RatcliffeSG . Clinical trial of Ospolot in epilepsy. Developmental Medicine and Child Neurology1963;5:313-5. [PMID: 13956541]">Ingram 1963</a>; <a href="./references#CD010062-bbs2-0006" title="GriffithsAW , SylvesterPE . Ospolot - a clinical trial of a new anticonvulsant. British Journal of Psychiatry1964;110:261-6. [DOI: 10.1192/bjp.110.465.261] [PMID: 14130479]">Griffiths 1964</a>; <a href="./references#CD010062-bbs2-0010" title="LivingstonS , VillamaterC , SakataY . Ospolot (sulthiame) in epilepsy. Diseases of the Nervous System1967;28(4):259-63. [PMID: 4381572]">Livingston 1967</a>). One study compared STM versus placebo as an addâon therapy in epilepsy (<a href="./references#CD010062-bbs2-0005" title="DebusOM , KurlemannG . Sulthiame in the primary therapy of West syndrome: a randomized, double-blind placebo-controlled add-on trial on baseline pyridoxine medication. Epilepsia2004;45(2):103-8. [PMID: 14738417]">Debus 2004</a>). One study compared STM versus placebo as monotherapy in healthy participants with no history of epilepsy, measuring axonal excitability of cortical neurons as a primary outcome (<a href="./references#CD010062-bbs2-0007" title="GroppaS , SiniatchkinM , SiebnerH , StephaniU . Reduction of motor cortex excitability by the anticonvulsant drug sulthiame: a TMS study. Epilepsia2006;47(Suppl 3):123-4, Abstract no: p474. SiniatchkinM , GroppaS , SiebnerH , StephaniU . A single dose of sulthiame induces a selective increase in resting motor threshold in human motor cortex: a transcranial magnetic stimulation study. Epilepsy Research2006;72(1):18-24. [PMID: 16930943]">Groppa 2006</a>). One study assessed the effects of STM in both epileptic and nonâepileptic participants (<a href="./references#CD010062-bbs2-0011" title="MoffattWR , SiddiquiAR , MacKayDN . The use of sulthiame with disturbed mentally subnormal patients. British Journal of Psychiatry1970;117(541):673-8. [PMID: 4395345]">Moffatt 1970</a>). One study that compared STM versus placebo as monotherapy in participants with BECTS was abandoned (<a href="./references#CD010062-bbs2-0009" title="ISRCTN66730162. Investigating the relationship between sleep disturbance and learning in children with benign epilepsy of childhood with centrotemporal spikes (BECCTS): a randomised double blind placebo controlled crossover trial. isrctn.com/ISRCTN66730162. [www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-001571-39]">ISRCTN66730162 2011</a>). </p> </section> </section> <section id="CD010062-sec-0047"> <h3 class="title">Risk of bias in included studies</h3> <p>Summaries of our judgements for each risk of bias domain, across the included studies, are presented in <a href="#CD010062-fig-0002">Figure 2</a> and <a href="#CD010062-fig-0003">Figure 3</a>. Reasons supporting our judgements, including quotations taken directly from the text publications and specific review author comments, can be found in the risk of bias tables in <a href="./references#CD010062-sec-0099" title="">Characteristics of included studies</a>. </p> <div class="figure" id="CD010062-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010062-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD010062-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010062-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD010062-sec-0048"> <h4 class="title">Allocation</h4> <p><a href="./references#CD010062-bbs2-0004" title='BastT , VÃ¶lpA , WolfC , RatingD . The influence of sulthiame on EEG in children with benign epilepsy with centrotemporal spikes (BECTS). Epilepsia2003;44(2):215-20. [PMID: 12558577]RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6-month randomized, double-blind, placebo-controlled study. Epilepsia2000;41(10):1284-8. [PMID: 11051123]RatingD , WolfC . Sulthiame vs placebo in the treatment of benign epilepsy with centrotemporal spikes ("rolandic" epilepsy). Epilepsia1999;40(Suppl 2):163. '>Rating 1999</a> stated that participants were divided into blocks of four according to a preâprepared list. The study authors did not explain how this list was formulated or how each block of four was assigned to treatment or placebo. The control group included a high proportion of males compared with females (69% versus 31%). <a href="./references#CD010062-bbs2-0003" title="Li Jimin, Li Zuohan, Jin Yongqing, Pan Daoming, Xu Peixi, Hu Dameng, Xu Min. A randomized controlled multicenter clinical study on sulthiame in the treatment of GTCS. Journal of Clinical Neurology2000;13(6):345-7. ">Li 2000</a> provided no information on how allocation was determined. The open group included a high proportion of males compared with females (70% versus 30%). <a href="./references#CD010062-bbs2-0001" title="BasnecA , SkarpaD , BarisicN , JurinM , Mucic-PucicB . The risk of second seizure in children with benign childhood epilepsy with centrotemporal spikes without treatment - a prospective study [Rizik javljanja drugog napadaja u nelijeÄene djece s benignom parcijalnom epilepsijom s centrotemporalnim Å¡iljaka - prospektivno istraÅ¾ivanje]. Acta Medica Croatica2005;59(1):59-62. [PMID: 15813357]">Basnec 2005</a> did not provide information on how allocation was determined. <a href="./references#CD010062-bbs2-0002" title="BorggraefeI , BonfertM , BastT , NeubauerBA , SchottenKJ , MassmannK , et al. Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study). European Journal of Paediatric Neurology2013;17(5):507-14. [DOI: 10.1016/j.ejpn.2013.03.014] [PMID: 23642492]BorggraefeI , BonfertM , GerstlL , HeinenF , NeubauerB . A double-blinded, randomized evaluation of neuropsychological and behavioral changes in children with benign epilepsy with centrotemporal spikes treated either with levetiracetam or sulthiame. Epilepsy Currents2015;15(Suppl 1):278, Abstract no: 2.04. TackeM , BorggraefeI , GerstlL , HeinenF , VillK , BonfertM , et al. Effects of levetiracetam and sulthiame on EEG in benign epilepsy with centrotemporal spikes: a randomized controlled trial. Seizure2018;56:115-20. [DOI: 10.1016/j.seizure.2018.01.015] [PMID: 29475094]TackeM , GerstlL , HeinenF , HeukaeuferI , BonfertM , BastT , et al. Effect of anticonvulsive treatment on neuropsychological performance in children with BECTS. European Journal of Paediatric Neurology2016;20(6):874-9. [DOI: 10.1016/j.ejpn.2016.07.015] [PMID: 27553576]TackeM . EEG changes in rolandic epilepsy under treatment with levetiracetam and sulthiame. European Journal of Paediatric Neurology2017;21(Suppl 1):e97, Abstract no: P2-5. [DOI: 10.1016/j.ejpn.2017.04.733]">Borggraefe 2013</a> stated that the randomisations list was generated at the central randomisations centre of the study medication manufacturer using permuted blocks. Participants were allocated to one to the two treatment groups in a 1:1 ratio. </p> </section> <section id="CD010062-sec-0049"> <h4 class="title">Blinding</h4> <p>In <a href="./references#CD010062-bbs2-0004" title='BastT , VÃ¶lpA , WolfC , RatingD . The influence of sulthiame on EEG in children with benign epilepsy with centrotemporal spikes (BECTS). Epilepsia2003;44(2):215-20. [PMID: 12558577]RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6-month randomized, double-blind, placebo-controlled study. Epilepsia2000;41(10):1284-8. [PMID: 11051123]RatingD , WolfC . Sulthiame vs placebo in the treatment of benign epilepsy with centrotemporal spikes ("rolandic" epilepsy). Epilepsia1999;40(Suppl 2):163. '>Rating 1999</a>, each participant had his or her designation held in a sealed, coded envelope that was kept by an investigator for emergency use only. <a href="./references#CD010062-bbs2-0003" title="Li Jimin, Li Zuohan, Jin Yongqing, Pan Daoming, Xu Peixi, Hu Dameng, Xu Min. A randomized controlled multicenter clinical study on sulthiame in the treatment of GTCS. Journal of Clinical Neurology2000;13(6):345-7. ">Li 2000</a> and <a href="./references#CD010062-bbs2-0001" title="BasnecA , SkarpaD , BarisicN , JurinM , Mucic-PucicB . The risk of second seizure in children with benign childhood epilepsy with centrotemporal spikes without treatment - a prospective study [Rizik javljanja drugog napadaja u nelijeÄene djece s benignom parcijalnom epilepsijom s centrotemporalnim Å¡iljaka - prospektivno istraÅ¾ivanje]. Acta Medica Croatica2005;59(1):59-62. [PMID: 15813357]">Basnec 2005</a> provided no information on how blinding was performed. <a href="./references#CD010062-bbs2-0002" title="BorggraefeI , BonfertM , BastT , NeubauerBA , SchottenKJ , MassmannK , et al. Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study). European Journal of Paediatric Neurology2013;17(5):507-14. [DOI: 10.1016/j.ejpn.2013.03.014] [PMID: 23642492]BorggraefeI , BonfertM , GerstlL , HeinenF , NeubauerB . A double-blinded, randomized evaluation of neuropsychological and behavioral changes in children with benign epilepsy with centrotemporal spikes treated either with levetiracetam or sulthiame. Epilepsy Currents2015;15(Suppl 1):278, Abstract no: 2.04. TackeM , BorggraefeI , GerstlL , HeinenF , VillK , BonfertM , et al. Effects of levetiracetam and sulthiame on EEG in benign epilepsy with centrotemporal spikes: a randomized controlled trial. Seizure2018;56:115-20. [DOI: 10.1016/j.seizure.2018.01.015] [PMID: 29475094]TackeM , GerstlL , HeinenF , HeukaeuferI , BonfertM , BastT , et al. Effect of anticonvulsive treatment on neuropsychological performance in children with BECTS. European Journal of Paediatric Neurology2016;20(6):874-9. [DOI: 10.1016/j.ejpn.2016.07.015] [PMID: 27553576]TackeM . EEG changes in rolandic epilepsy under treatment with levetiracetam and sulthiame. European Journal of Paediatric Neurology2017;21(Suppl 1):e97, Abstract no: P2-5. [DOI: 10.1016/j.ejpn.2017.04.733]">Borggraefe 2013</a> provided no details regarding blinding of participants, personnel, and outcome assessors. </p> </section> <section id="CD010062-sec-0050"> <h4 class="title">Incomplete outcome data</h4> <p><a href="./references#CD010062-bbs2-0004" title='BastT , VÃ¶lpA , WolfC , RatingD . The influence of sulthiame on EEG in children with benign epilepsy with centrotemporal spikes (BECTS). Epilepsia2003;44(2):215-20. [PMID: 12558577]RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6-month randomized, double-blind, placebo-controlled study. Epilepsia2000;41(10):1284-8. [PMID: 11051123]RatingD , WolfC . Sulthiame vs placebo in the treatment of benign epilepsy with centrotemporal spikes ("rolandic" epilepsy). Epilepsia1999;40(Suppl 2):163. '>Rating 1999</a> was terminated early after an interim analysis found superiority in the intervention group. Two participants from each group were removed from the study at this point. <a href="./references#CD010062-bbs2-0004" title='BastT , VÃ¶lpA , WolfC , RatingD . The influence of sulthiame on EEG in children with benign epilepsy with centrotemporal spikes (BECTS). Epilepsia2003;44(2):215-20. [PMID: 12558577]RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6-month randomized, double-blind, placebo-controlled study. Epilepsia2000;41(10):1284-8. [PMID: 11051123]RatingD , WolfC . Sulthiame vs placebo in the treatment of benign epilepsy with centrotemporal spikes ("rolandic" epilepsy). Epilepsia1999;40(Suppl 2):163. '>Rating 1999</a> reported the following withdrawals from the study after randomisation: six participants in the intervention group (four because of seizure and two due to early termination of the study) and 25 participants in the placebo group (21 because of seizure, two due to withdrawal of parental consent, and two as a result of early termination of the study). The paper defined the following events as treatment failure events: participants experiencing a first seizure after a sevenâday runâin period; having intolerable adverse effects; developing another epileptic syndrome; or being terminated from the trial by their parents or by themselves. It is unclear based on the published paper whether an intentionâtoâtreat analysis was performed. <a href="./references#CD010062-bbs2-0003" title="Li Jimin, Li Zuohan, Jin Yongqing, Pan Daoming, Xu Peixi, Hu Dameng, Xu Min. A randomized controlled multicenter clinical study on sulthiame in the treatment of GTCS. Journal of Clinical Neurology2000;13(6):345-7. ">Li 2000</a> provided no information on treatment withdrawal. All participants who were randomly assigned were included in the final analysis. It is plausible that this indicates that no participants withdrew from treatment; however, this is not explicitly stated in the publication. <a href="./references#CD010062-bbs2-0001" title="BasnecA , SkarpaD , BarisicN , JurinM , Mucic-PucicB . The risk of second seizure in children with benign childhood epilepsy with centrotemporal spikes without treatment - a prospective study [Rizik javljanja drugog napadaja u nelijeÄene djece s benignom parcijalnom epilepsijom s centrotemporalnim Å¡iljaka - prospektivno istraÅ¾ivanje]. Acta Medica Croatica2005;59(1):59-62. [PMID: 15813357]">Basnec 2005</a> stated that four participants withdrew from treatment during the study, but to which groups these participants had been assigned is not reported. Analysis was performed without these participants, rather than by intentionâtoâtreat approach. <a href="./references#CD010062-bbs2-0002" title="BorggraefeI , BonfertM , BastT , NeubauerBA , SchottenKJ , MassmannK , et al. Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study). European Journal of Paediatric Neurology2013;17(5):507-14. [DOI: 10.1016/j.ejpn.2013.03.014] [PMID: 23642492]BorggraefeI , BonfertM , GerstlL , HeinenF , NeubauerB . A double-blinded, randomized evaluation of neuropsychological and behavioral changes in children with benign epilepsy with centrotemporal spikes treated either with levetiracetam or sulthiame. Epilepsy Currents2015;15(Suppl 1):278, Abstract no: 2.04. TackeM , BorggraefeI , GerstlL , HeinenF , VillK , BonfertM , et al. Effects of levetiracetam and sulthiame on EEG in benign epilepsy with centrotemporal spikes: a randomized controlled trial. Seizure2018;56:115-20. [DOI: 10.1016/j.seizure.2018.01.015] [PMID: 29475094]TackeM , GerstlL , HeinenF , HeukaeuferI , BonfertM , BastT , et al. Effect of anticonvulsive treatment on neuropsychological performance in children with BECTS. European Journal of Paediatric Neurology2016;20(6):874-9. [DOI: 10.1016/j.ejpn.2016.07.015] [PMID: 27553576]TackeM . EEG changes in rolandic epilepsy under treatment with levetiracetam and sulthiame. European Journal of Paediatric Neurology2017;21(Suppl 1):e97, Abstract no: P2-5. [DOI: 10.1016/j.ejpn.2017.04.733]">Borggraefe 2013</a> stated that one participant in the control group was excluded from the final analysis due to a protocol violation. Attrition was fully reported, and intentionâtoâtreat analysis was used. </p> </section> <section id="CD010062-sec-0051"> <h4 class="title">Selective reporting</h4> <p><a href="./references#CD010062-bbs2-0004" title='BastT , VÃ¶lpA , WolfC , RatingD . The influence of sulthiame on EEG in children with benign epilepsy with centrotemporal spikes (BECTS). Epilepsia2003;44(2):215-20. [PMID: 12558577]RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6-month randomized, double-blind, placebo-controlled study. Epilepsia2000;41(10):1284-8. [PMID: 11051123]RatingD , WolfC . Sulthiame vs placebo in the treatment of benign epilepsy with centrotemporal spikes ("rolandic" epilepsy). Epilepsia1999;40(Suppl 2):163. '>Rating 1999</a> reported that a total of 31 participants withdrew from treatment, but it is not stated whether intentionâtoâtreat analysis was performed. The total number of adverse effects experienced by each group was reported; however, data on the individual frequency of each adverse effect were not reported. Data were not reported on time to treatment withdrawal; proportion of participants with a reduction in seizure frequency of 50% or greater; proportion of participants seizureâfree at 12 months; or quality of life scale scores. <a href="./references#CD010062-bbs2-0003" title="Li Jimin, Li Zuohan, Jin Yongqing, Pan Daoming, Xu Peixi, Hu Dameng, Xu Min. A randomized controlled multicenter clinical study on sulthiame in the treatment of GTCS. Journal of Clinical Neurology2000;13(6):345-7. ">Li 2000</a> provided no data on time to treatment withdrawal; proportion of participants who withdrew from treatment; proportion of participants with a reduction in seizure frequency of 50% or greater; proportion of participants seizureâfree at 12 months; or quality of life scale scores. Adverse effects, including individual frequencies of each adverse effect, were reported; however, data for the intervention group were combined with data from a much larger, unblinded, open group that had an unusually large proportion of male participants compared with the other groups. It is unclear whether data provided on adverse effects relate to number of events or number of participants experiencing an adverse effect. It was not possible to assess this domain for <a href="./references#CD010062-bbs2-0001" title="BasnecA , SkarpaD , BarisicN , JurinM , Mucic-PucicB . The risk of second seizure in children with benign childhood epilepsy with centrotemporal spikes without treatment - a prospective study [Rizik javljanja drugog napadaja u nelijeÄene djece s benignom parcijalnom epilepsijom s centrotemporalnim Å¡iljaka - prospektivno istraÅ¾ivanje]. Acta Medica Croatica2005;59(1):59-62. [PMID: 15813357]">Basnec 2005</a> because a reliable English language fullâtext version of the study was not available. In <a href="./references#CD010062-bbs2-0002" title="BorggraefeI , BonfertM , BastT , NeubauerBA , SchottenKJ , MassmannK , et al. Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study). European Journal of Paediatric Neurology2013;17(5):507-14. [DOI: 10.1016/j.ejpn.2013.03.014] [PMID: 23642492]BorggraefeI , BonfertM , GerstlL , HeinenF , NeubauerB . A double-blinded, randomized evaluation of neuropsychological and behavioral changes in children with benign epilepsy with centrotemporal spikes treated either with levetiracetam or sulthiame. Epilepsy Currents2015;15(Suppl 1):278, Abstract no: 2.04. TackeM , BorggraefeI , GerstlL , HeinenF , VillK , BonfertM , et al. Effects of levetiracetam and sulthiame on EEG in benign epilepsy with centrotemporal spikes: a randomized controlled trial. Seizure2018;56:115-20. [DOI: 10.1016/j.seizure.2018.01.015] [PMID: 29475094]TackeM , GerstlL , HeinenF , HeukaeuferI , BonfertM , BastT , et al. Effect of anticonvulsive treatment on neuropsychological performance in children with BECTS. European Journal of Paediatric Neurology2016;20(6):874-9. [DOI: 10.1016/j.ejpn.2016.07.015] [PMID: 27553576]TackeM . EEG changes in rolandic epilepsy under treatment with levetiracetam and sulthiame. European Journal of Paediatric Neurology2017;21(Suppl 1):e97, Abstract no: P2-5. [DOI: 10.1016/j.ejpn.2017.04.733]">Borggraefe 2013</a>, all expected and prespecified outcomes were reported in the results section. We have also presented outcome reporting bias for all studies in an ORBIT table (<a href="#CD010062-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD010062-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="ORBIT table" data-id="CD010062-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-FIG-04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>ORBIT table</p> </div> </div> </div> </section> <section id="CD010062-sec-0052"> <h4 class="title">Other potential sources of bias</h4> <p><a href="./references#CD010062-bbs2-0004" title='BastT , VÃ¶lpA , WolfC , RatingD . The influence of sulthiame on EEG in children with benign epilepsy with centrotemporal spikes (BECTS). Epilepsia2003;44(2):215-20. [PMID: 12558577]RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6-month randomized, double-blind, placebo-controlled study. Epilepsia2000;41(10):1284-8. [PMID: 11051123]RatingD , WolfC . Sulthiame vs placebo in the treatment of benign epilepsy with centrotemporal spikes ("rolandic" epilepsy). Epilepsia1999;40(Suppl 2):163. '>Rating 1999</a> utilised clearly stated inclusion and exclusion criteria. <a href="./references#CD010062-bbs2-0003" title="Li Jimin, Li Zuohan, Jin Yongqing, Pan Daoming, Xu Peixi, Hu Dameng, Xu Min. A randomized controlled multicenter clinical study on sulthiame in the treatment of GTCS. Journal of Clinical Neurology2000;13(6):345-7. ">Li 2000</a> provided clear inclusion criteria based on a recent history of GTCS; however, no information was provided on inclusion or exclusion criteria based on participant age, weight, comorbidities, or previous AED use. The study authors combined treatment and open groups when performing an analysis of adverse effects, providing no separate data for the intervention group alone. <a href="./references#CD010062-bbs2-0001" title="BasnecA , SkarpaD , BarisicN , JurinM , Mucic-PucicB . The risk of second seizure in children with benign childhood epilepsy with centrotemporal spikes without treatment - a prospective study [Rizik javljanja drugog napadaja u nelijeÄene djece s benignom parcijalnom epilepsijom s centrotemporalnim Å¡iljaka - prospektivno istraÅ¾ivanje]. Acta Medica Croatica2005;59(1):59-62. [PMID: 15813357]">Basnec 2005</a> provided clear inclusion criteria, based on age and a diagnosis of BECTS with a single seizure and no AED treatment, in the abstract; however, as an English version of the full text was not available, it was not possible to fully appraise the inclusion and exclusion criteria for this study. <a href="./references#CD010062-bbs2-0002" title="BorggraefeI , BonfertM , BastT , NeubauerBA , SchottenKJ , MassmannK , et al. Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study). European Journal of Paediatric Neurology2013;17(5):507-14. [DOI: 10.1016/j.ejpn.2013.03.014] [PMID: 23642492]BorggraefeI , BonfertM , GerstlL , HeinenF , NeubauerB . A double-blinded, randomized evaluation of neuropsychological and behavioral changes in children with benign epilepsy with centrotemporal spikes treated either with levetiracetam or sulthiame. Epilepsy Currents2015;15(Suppl 1):278, Abstract no: 2.04. TackeM , BorggraefeI , GerstlL , HeinenF , VillK , BonfertM , et al. Effects of levetiracetam and sulthiame on EEG in benign epilepsy with centrotemporal spikes: a randomized controlled trial. Seizure2018;56:115-20. [DOI: 10.1016/j.seizure.2018.01.015] [PMID: 29475094]TackeM , GerstlL , HeinenF , HeukaeuferI , BonfertM , BastT , et al. Effect of anticonvulsive treatment on neuropsychological performance in children with BECTS. European Journal of Paediatric Neurology2016;20(6):874-9. [DOI: 10.1016/j.ejpn.2016.07.015] [PMID: 27553576]TackeM . EEG changes in rolandic epilepsy under treatment with levetiracetam and sulthiame. European Journal of Paediatric Neurology2017;21(Suppl 1):e97, Abstract no: P2-5. [DOI: 10.1016/j.ejpn.2017.04.733]">Borggraefe 2013</a> utilised clearly stated inclusion and exclusion criteria. This study was funded in part by UCB Pharma SA. </p> </section> </section> <section id="CD010062-sec-0053"> <h3 class="title" id="CD010062-sec-0053">Effects of interventions</h3> <p>See: <a href="./full#CD010062-tbl-0001"><b>Summary of findings 1</b> Sulthiame compared to placebo for epilepsy</a>; <a href="./full#CD010062-tbl-0002"><b>Summary of findings 2</b> Sulthiame compared with levetiracetam for epilepsy</a>; <a href="./full#CD010062-tbl-0003"><b>Summary of findings 3</b> Sulthiame compared with phenytoin for epilepsy</a> </p> <p>See <a href="./full#CD010062-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD010062-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD010062-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD010062-sec-0054"> <h4 class="title">Sulthiame versus placebo</h4> <p>Two included studies involving a total of 100 randomised participants compared sulthiame versus placebo (<a href="./references#CD010062-bbs2-0004" title='BastT , VÃ¶lpA , WolfC , RatingD . The influence of sulthiame on EEG in children with benign epilepsy with centrotemporal spikes (BECTS). Epilepsia2003;44(2):215-20. [PMID: 12558577]RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6-month randomized, double-blind, placebo-controlled study. Epilepsia2000;41(10):1284-8. [PMID: 11051123]RatingD , WolfC . Sulthiame vs placebo in the treatment of benign epilepsy with centrotemporal spikes ("rolandic" epilepsy). Epilepsia1999;40(Suppl 2):163. '>Rating 1999</a>; <a href="./references#CD010062-bbs2-0001" title="BasnecA , SkarpaD , BarisicN , JurinM , Mucic-PucicB . The risk of second seizure in children with benign childhood epilepsy with centrotemporal spikes without treatment - a prospective study [Rizik javljanja drugog napadaja u nelijeÄene djece s benignom parcijalnom epilepsijom s centrotemporalnim Å¡iljaka - prospektivno istraÅ¾ivanje]. Acta Medica Croatica2005;59(1):59-62. [PMID: 15813357]">Basnec 2005</a>). </p> <section id="CD010062-sec-0055"> <h5 class="title">Primary outcome</h5> <section id="CD010062-sec-0056"> <h6 class="title">Treatment withdrawal</h6> <p>No data were reported for this outcome.</p> </section> </section> <section id="CD010062-sec-0057"> <h5 class="title">Secondary outcomes</h5> <section id="CD010062-sec-0058"> <h6 class="title">Seizure freedom</h6> <p>No data were reported for this outcome.</p> </section> <section id="CD010062-sec-0059"> <h6 class="title">Adverse effects</h6> <p><a href="./references#CD010062-bbs2-0001" title="BasnecA , SkarpaD , BarisicN , JurinM , Mucic-PucicB . The risk of second seizure in children with benign childhood epilepsy with centrotemporal spikes without treatment - a prospective study [Rizik javljanja drugog napadaja u nelijeÄene djece s benignom parcijalnom epilepsijom s centrotemporalnim Å¡iljaka - prospektivno istraÅ¾ivanje]. Acta Medica Croatica2005;59(1):59-62. [PMID: 15813357]">Basnec 2005</a> provided no data on adverse effects in the abstract. </p> <p><a href="./references#CD010062-bbs2-0004" title='BastT , VÃ¶lpA , WolfC , RatingD . The influence of sulthiame on EEG in children with benign epilepsy with centrotemporal spikes (BECTS). Epilepsia2003;44(2):215-20. [PMID: 12558577]RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6-month randomized, double-blind, placebo-controlled study. Epilepsia2000;41(10):1284-8. [PMID: 11051123]RatingD , WolfC . Sulthiame vs placebo in the treatment of benign epilepsy with centrotemporal spikes ("rolandic" epilepsy). Epilepsia1999;40(Suppl 2):163. '>Rating 1999</a> did not report the number of participants who experienced adverse effects. They did report a total of 60 events (1.9 events per participant) in the intervention group and 33 events (0.9 events per participant) in the placebo group. Adverse effects that occurred more than once included leukopenia, loss of strength, and fatigue. </p> </section> <section id="CD010062-sec-0060"> <h6 class="title">Quality of life</h6> <p>No data were reported for this outcome.</p> </section> </section> </section> <section id="CD010062-sec-0061"> <h4 class="title">Sulthiame versus levetiracetam</h4> <p>One included study involving a total of 43 randomised participants compared sulthiame versus levetiracetam (<a href="./references#CD010062-bbs2-0002" title="BorggraefeI , BonfertM , BastT , NeubauerBA , SchottenKJ , MassmannK , et al. Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study). European Journal of Paediatric Neurology2013;17(5):507-14. [DOI: 10.1016/j.ejpn.2013.03.014] [PMID: 23642492]BorggraefeI , BonfertM , GerstlL , HeinenF , NeubauerB . A double-blinded, randomized evaluation of neuropsychological and behavioral changes in children with benign epilepsy with centrotemporal spikes treated either with levetiracetam or sulthiame. Epilepsy Currents2015;15(Suppl 1):278, Abstract no: 2.04. TackeM , BorggraefeI , GerstlL , HeinenF , VillK , BonfertM , et al. Effects of levetiracetam and sulthiame on EEG in benign epilepsy with centrotemporal spikes: a randomized controlled trial. Seizure2018;56:115-20. [DOI: 10.1016/j.seizure.2018.01.015] [PMID: 29475094]TackeM , GerstlL , HeinenF , HeukaeuferI , BonfertM , BastT , et al. Effect of anticonvulsive treatment on neuropsychological performance in children with BECTS. European Journal of Paediatric Neurology2016;20(6):874-9. [DOI: 10.1016/j.ejpn.2016.07.015] [PMID: 27553576]TackeM . EEG changes in rolandic epilepsy under treatment with levetiracetam and sulthiame. European Journal of Paediatric Neurology2017;21(Suppl 1):e97, Abstract no: P2-5. [DOI: 10.1016/j.ejpn.2017.04.733]">Borggraefe 2013</a>). </p> <section id="CD010062-sec-0062"> <h5 class="title">Primary outcome</h5> <section id="CD010062-sec-0063"> <h6 class="title">Treatment withdrawal</h6> <p><a href="./references#CD010062-bbs2-0002" title="BorggraefeI , BonfertM , BastT , NeubauerBA , SchottenKJ , MassmannK , et al. Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study). European Journal of Paediatric Neurology2013;17(5):507-14. [DOI: 10.1016/j.ejpn.2013.03.014] [PMID: 23642492]BorggraefeI , BonfertM , GerstlL , HeinenF , NeubauerB . A double-blinded, randomized evaluation of neuropsychological and behavioral changes in children with benign epilepsy with centrotemporal spikes treated either with levetiracetam or sulthiame. Epilepsy Currents2015;15(Suppl 1):278, Abstract no: 2.04. TackeM , BorggraefeI , GerstlL , HeinenF , VillK , BonfertM , et al. Effects of levetiracetam and sulthiame on EEG in benign epilepsy with centrotemporal spikes: a randomized controlled trial. Seizure2018;56:115-20. [DOI: 10.1016/j.seizure.2018.01.015] [PMID: 29475094]TackeM , GerstlL , HeinenF , HeukaeuferI , BonfertM , BastT , et al. Effect of anticonvulsive treatment on neuropsychological performance in children with BECTS. European Journal of Paediatric Neurology2016;20(6):874-9. [DOI: 10.1016/j.ejpn.2016.07.015] [PMID: 27553576]TackeM . EEG changes in rolandic epilepsy under treatment with levetiracetam and sulthiame. European Journal of Paediatric Neurology2017;21(Suppl 1):e97, Abstract no: P2-5. [DOI: 10.1016/j.ejpn.2017.04.733]">Borggraefe 2013</a> presented data for this outcome (<a href="./references#CD010062-fig-0005" title="">Analysis 1.1</a>), reporting that 3 of 22 participants in the STM group and 9 of 21 participants in the LEV group withdrew from treatment (risk ratio (RR) 0.32, 95% confidence interval (Cl) 0.10 to 1.02). The total number of dropouts caused either by seizure recurrence or adverse reaction was therefore significantly higher in the LEV treatment arm compared to the STM treatment arm. </p> </section> </section> <section id="CD010062-sec-0064"> <h5 class="title">Secondary outcomes</h5> <section id="CD010062-sec-0065"> <h6 class="title">Seizure freedom</h6> <p><a href="./references#CD010062-bbs2-0002" title="BorggraefeI , BonfertM , BastT , NeubauerBA , SchottenKJ , MassmannK , et al. Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study). European Journal of Paediatric Neurology2013;17(5):507-14. [DOI: 10.1016/j.ejpn.2013.03.014] [PMID: 23642492]BorggraefeI , BonfertM , GerstlL , HeinenF , NeubauerB . A double-blinded, randomized evaluation of neuropsychological and behavioral changes in children with benign epilepsy with centrotemporal spikes treated either with levetiracetam or sulthiame. Epilepsy Currents2015;15(Suppl 1):278, Abstract no: 2.04. TackeM , BorggraefeI , GerstlL , HeinenF , VillK , BonfertM , et al. Effects of levetiracetam and sulthiame on EEG in benign epilepsy with centrotemporal spikes: a randomized controlled trial. Seizure2018;56:115-20. [DOI: 10.1016/j.seizure.2018.01.015] [PMID: 29475094]TackeM , GerstlL , HeinenF , HeukaeuferI , BonfertM , BastT , et al. Effect of anticonvulsive treatment on neuropsychological performance in children with BECTS. European Journal of Paediatric Neurology2016;20(6):874-9. [DOI: 10.1016/j.ejpn.2016.07.015] [PMID: 27553576]TackeM . EEG changes in rolandic epilepsy under treatment with levetiracetam and sulthiame. European Journal of Paediatric Neurology2017;21(Suppl 1):e97, Abstract no: P2-5. [DOI: 10.1016/j.ejpn.2017.04.733]">Borggraefe 2013</a> presented data for this outcome (<a href="./references#CD010062-fig-0006" title="">Analysis 1.2</a>), reporting that 20 participants in the STM group and 17 in the LEV group attained seizure freedom (RR 1.12, 95% Cl 0.88 to 1.44). However, the analysis indicated that the results were inconclusive, and we were unable to determine whether there was an effect of sulthiame on seizure freedom. </p> </section> <section id="CD010062-sec-0066"> <h6 class="title">Adverse effects</h6> <p><a href="./references#CD010062-bbs2-0002" title="BorggraefeI , BonfertM , BastT , NeubauerBA , SchottenKJ , MassmannK , et al. Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study). European Journal of Paediatric Neurology2013;17(5):507-14. [DOI: 10.1016/j.ejpn.2013.03.014] [PMID: 23642492]BorggraefeI , BonfertM , GerstlL , HeinenF , NeubauerB . A double-blinded, randomized evaluation of neuropsychological and behavioral changes in children with benign epilepsy with centrotemporal spikes treated either with levetiracetam or sulthiame. Epilepsy Currents2015;15(Suppl 1):278, Abstract no: 2.04. TackeM , BorggraefeI , GerstlL , HeinenF , VillK , BonfertM , et al. Effects of levetiracetam and sulthiame on EEG in benign epilepsy with centrotemporal spikes: a randomized controlled trial. Seizure2018;56:115-20. [DOI: 10.1016/j.seizure.2018.01.015] [PMID: 29475094]TackeM , GerstlL , HeinenF , HeukaeuferI , BonfertM , BastT , et al. Effect of anticonvulsive treatment on neuropsychological performance in children with BECTS. European Journal of Paediatric Neurology2016;20(6):874-9. [DOI: 10.1016/j.ejpn.2016.07.015] [PMID: 27553576]TackeM . EEG changes in rolandic epilepsy under treatment with levetiracetam and sulthiame. European Journal of Paediatric Neurology2017;21(Suppl 1):e97, Abstract no: P2-5. [DOI: 10.1016/j.ejpn.2017.04.733]">Borggraefe 2013</a> reported that total adverse reactions were higher in participants receiving LEV compared to those receiving STM, though not reaching statistical significance (23.8% and 4.5%, respectively). General symptoms (weight gain or loss, sleep disorder, fatigue, skin lesions, hiccup) were as follows: 17 in the STM group versus 15 in the LEV group (RR 1.08, 95% Cl 0.76 to 1.54). The following individual adverse effects were reported. </p> <p> <ul id="CD010062-list-0013"> <li> <p>Central nervous system: 16 in STM group versus 13 in LEV group (RR 1.17, 95% CI 0.77 to 1.79). </p> </li> <li> <p>Behaviour: 13 in STM group versus 13 in LEV group (RR 0.95, 95% CI 0.59 to 1.55).</p> </li> <li> <p>Airways: 14 in STM group versus 5 in LEV group (RR 2.67, 95% CI 1.17 to 6.12).</p> </li> <li> <p>Cardiac: 1 in STM group versus 0 in LEV group (RR 2.87, 95% CI 0.12 to 66.75).</p> </li> <li> <p>Gastrointestinal: 8 in STM group versus 10 in LEV group (RR 0.76, 95% CI 0.37 to 1.56).</p> </li> <li> <p>Bones and muscles: 4 in STM group versus 4 in LEV group (RR 0.95, 95% CI 0.27 to 3.33).</p> </li> <li> <p>Others: 5 in STM group versus 4 in LEV group (RR 1.19, 95% CI 0.37 to 3.85).</p> </li> </ul> </p> </section> <section id="CD010062-sec-0067"> <h6 class="title">Quality of life</h6> <p>No data were reported for this outcome.</p> </section> </section> </section> <section id="CD010062-sec-0068"> <h4 class="title">Sulthiame versus phenytoin</h4> <p>One included study involving a total of 146 randomised participants compared sulthiame versus phenytoin (<a href="./references#CD010062-bbs2-0003" title="Li Jimin, Li Zuohan, Jin Yongqing, Pan Daoming, Xu Peixi, Hu Dameng, Xu Min. A randomized controlled multicenter clinical study on sulthiame in the treatment of GTCS. Journal of Clinical Neurology2000;13(6):345-7. ">Li 2000</a>). </p> <section id="CD010062-sec-0069"> <h5 class="title">Primary outcome</h5> <section id="CD010062-sec-0070"> <h6 class="title">Treatment withdrawal</h6> <p>No data were reported for this outcome.</p> </section> </section> <section id="CD010062-sec-0071"> <h5 class="title">Secondary outcomes</h5> <section id="CD010062-sec-0072"> <h6 class="title">Seizure freedom</h6> <p>No data were reported for this outcome.</p> </section> <section id="CD010062-sec-0073"> <h6 class="title">Adverse effects</h6> <p><a href="./references#CD010062-bbs2-0003" title="Li Jimin, Li Zuohan, Jin Yongqing, Pan Daoming, Xu Peixi, Hu Dameng, Xu Min. A randomized controlled multicenter clinical study on sulthiame in the treatment of GTCS. Journal of Clinical Neurology2000;13(6):345-7. ">Li 2000</a> reported a total of 30 adverse effects in the combined intervention and open group, and 8 in the PHT group. The overall RR for STM compared with PHT was 1.05 (95% CI 0.54 to 2.07). </p> <p>The following individual adverse effects were reported.</p> <p> <ul id="CD010062-list-0014"> <li> <p>Paraesthesia: 14 in STM groups versus 0 in PHT group (RR 8.32, 95% CI 0.51 to 135.82).</p> </li> <li> <p>Dizziness: 5 in STM groups versus 0 in PHT group (RR 3.16, 95% CI 0.18 to 55.62).</p> </li> <li> <p>Headache: 2 in STM groups versus 0 in PHT group (RR 1.43, 95% CI 0.07 to 29.15).</p> </li> <li> <p>Anorexia: 3 in STM groups versus 2 in PHT group (RR 0.42, 95% CI 0.07 to 2.41).</p> </li> <li> <p>Rash: 1 in STM groups versus 1 in PHT group (RR 0.28, 95% CI 0.02 to 4.36).</p> </li> <li> <p>Gingival hyperplasia: 0 in STM groups versus 4 in PHT group (RR 0.03, 95% CI 0.00 to 0.58). </p> </li> <li> <p>Others: 5 in STM groups versus 1 in PHT group (RR 1.40, 95% CI 0.17 to 11.59).</p> </li> </ul> </p> <p>No significant difference in the total number of adverse effects was noted between the two groups (P = 0.88), and gingival hyperplasia was the only individual adverse effect showing a significant difference between the STM and PHT groups (P = 0.02). </p> </section> <section id="CD010062-sec-0074"> <h6 class="title">Quality of life</h6> <p>No data were reported for this outcome.</p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010062-sec-0075" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010062-sec-0075"></div> <section id="CD010062-sec-0076"> <h3 class="title" id="CD010062-sec-0076">Summary of main results</h3> <p>We included four published studies in the review. Both <a href="./references#CD010062-bbs2-0004" title='BastT , VÃ¶lpA , WolfC , RatingD . The influence of sulthiame on EEG in children with benign epilepsy with centrotemporal spikes (BECTS). Epilepsia2003;44(2):215-20. [PMID: 12558577]RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6-month randomized, double-blind, placebo-controlled study. Epilepsia2000;41(10):1284-8. [PMID: 11051123]RatingD , WolfC . Sulthiame vs placebo in the treatment of benign epilepsy with centrotemporal spikes ("rolandic" epilepsy). Epilepsia1999;40(Suppl 2):163. '>Rating 1999</a> and <a href="./references#CD010062-bbs2-0001" title="BasnecA , SkarpaD , BarisicN , JurinM , Mucic-PucicB . The risk of second seizure in children with benign childhood epilepsy with centrotemporal spikes without treatment - a prospective study [Rizik javljanja drugog napadaja u nelijeÄene djece s benignom parcijalnom epilepsijom s centrotemporalnim Å¡iljaka - prospektivno istraÅ¾ivanje]. Acta Medica Croatica2005;59(1):59-62. [PMID: 15813357]">Basnec 2005</a> compared STM as monotherapy versus placebo for treatment of BECTS. <a href="./references#CD010062-bbs2-0003" title="Li Jimin, Li Zuohan, Jin Yongqing, Pan Daoming, Xu Peixi, Hu Dameng, Xu Min. A randomized controlled multicenter clinical study on sulthiame in the treatment of GTCS. Journal of Clinical Neurology2000;13(6):345-7. ">Li 2000</a> compared STM versus PHT for treatment of GTCS. <a href="./references#CD010062-bbs2-0002" title="BorggraefeI , BonfertM , BastT , NeubauerBA , SchottenKJ , MassmannK , et al. Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study). European Journal of Paediatric Neurology2013;17(5):507-14. [DOI: 10.1016/j.ejpn.2013.03.014] [PMID: 23642492]BorggraefeI , BonfertM , GerstlL , HeinenF , NeubauerB . A double-blinded, randomized evaluation of neuropsychological and behavioral changes in children with benign epilepsy with centrotemporal spikes treated either with levetiracetam or sulthiame. Epilepsy Currents2015;15(Suppl 1):278, Abstract no: 2.04. TackeM , BorggraefeI , GerstlL , HeinenF , VillK , BonfertM , et al. Effects of levetiracetam and sulthiame on EEG in benign epilepsy with centrotemporal spikes: a randomized controlled trial. Seizure2018;56:115-20. [DOI: 10.1016/j.seizure.2018.01.015] [PMID: 29475094]TackeM , GerstlL , HeinenF , HeukaeuferI , BonfertM , BastT , et al. Effect of anticonvulsive treatment on neuropsychological performance in children with BECTS. European Journal of Paediatric Neurology2016;20(6):874-9. [DOI: 10.1016/j.ejpn.2016.07.015] [PMID: 27553576]TackeM . EEG changes in rolandic epilepsy under treatment with levetiracetam and sulthiame. European Journal of Paediatric Neurology2017;21(Suppl 1):e97, Abstract no: P2-5. [DOI: 10.1016/j.ejpn.2017.04.733]">Borggraefe 2013</a> compared STM versus LEV for treatment of BECTS. <a href="./references#CD010062-bbs2-0003" title="Li Jimin, Li Zuohan, Jin Yongqing, Pan Daoming, Xu Peixi, Hu Dameng, Xu Min. A randomized controlled multicenter clinical study on sulthiame in the treatment of GTCS. Journal of Clinical Neurology2000;13(6):345-7. ">Li 2000</a> was published in Chinese, and an English translation of the full manuscript was obtained for the purposes of this review. <a href="./references#CD010062-bbs2-0001" title="BasnecA , SkarpaD , BarisicN , JurinM , Mucic-PucicB . The risk of second seizure in children with benign childhood epilepsy with centrotemporal spikes without treatment - a prospective study [Rizik javljanja drugog napadaja u nelijeÄene djece s benignom parcijalnom epilepsijom s centrotemporalnim Å¡iljaka - prospektivno istraÅ¾ivanje]. Acta Medica Croatica2005;59(1):59-62. [PMID: 15813357]">Basnec 2005</a> was published in Croatian. At the time of publication of this review, the English translation of the abstract but not the full manuscript was available. None of the included studies reported data on quality of life scale scores. </p> <p><a href="./references#CD010062-bbs2-0002" title="BorggraefeI , BonfertM , BastT , NeubauerBA , SchottenKJ , MassmannK , et al. Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study). European Journal of Paediatric Neurology2013;17(5):507-14. [DOI: 10.1016/j.ejpn.2013.03.014] [PMID: 23642492]BorggraefeI , BonfertM , GerstlL , HeinenF , NeubauerB . A double-blinded, randomized evaluation of neuropsychological and behavioral changes in children with benign epilepsy with centrotemporal spikes treated either with levetiracetam or sulthiame. Epilepsy Currents2015;15(Suppl 1):278, Abstract no: 2.04. TackeM , BorggraefeI , GerstlL , HeinenF , VillK , BonfertM , et al. Effects of levetiracetam and sulthiame on EEG in benign epilepsy with centrotemporal spikes: a randomized controlled trial. Seizure2018;56:115-20. [DOI: 10.1016/j.seizure.2018.01.015] [PMID: 29475094]TackeM , GerstlL , HeinenF , HeukaeuferI , BonfertM , BastT , et al. Effect of anticonvulsive treatment on neuropsychological performance in children with BECTS. European Journal of Paediatric Neurology2016;20(6):874-9. [DOI: 10.1016/j.ejpn.2016.07.015] [PMID: 27553576]TackeM . EEG changes in rolandic epilepsy under treatment with levetiracetam and sulthiame. European Journal of Paediatric Neurology2017;21(Suppl 1):e97, Abstract no: P2-5. [DOI: 10.1016/j.ejpn.2017.04.733]">Borggraefe 2013</a> reported data on treatment withdrawal: the total number of dropouts caused either by seizure recurrence or adverse reaction was significantly higher in the LEV treatment arm compared to the STM treatment arm. <a href="./references#CD010062-bbs2-0002" title="BorggraefeI , BonfertM , BastT , NeubauerBA , SchottenKJ , MassmannK , et al. Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study). European Journal of Paediatric Neurology2013;17(5):507-14. [DOI: 10.1016/j.ejpn.2013.03.014] [PMID: 23642492]BorggraefeI , BonfertM , GerstlL , HeinenF , NeubauerB . A double-blinded, randomized evaluation of neuropsychological and behavioral changes in children with benign epilepsy with centrotemporal spikes treated either with levetiracetam or sulthiame. Epilepsy Currents2015;15(Suppl 1):278, Abstract no: 2.04. TackeM , BorggraefeI , GerstlL , HeinenF , VillK , BonfertM , et al. Effects of levetiracetam and sulthiame on EEG in benign epilepsy with centrotemporal spikes: a randomized controlled trial. Seizure2018;56:115-20. [DOI: 10.1016/j.seizure.2018.01.015] [PMID: 29475094]TackeM , GerstlL , HeinenF , HeukaeuferI , BonfertM , BastT , et al. Effect of anticonvulsive treatment on neuropsychological performance in children with BECTS. European Journal of Paediatric Neurology2016;20(6):874-9. [DOI: 10.1016/j.ejpn.2016.07.015] [PMID: 27553576]TackeM . EEG changes in rolandic epilepsy under treatment with levetiracetam and sulthiame. European Journal of Paediatric Neurology2017;21(Suppl 1):e97, Abstract no: P2-5. [DOI: 10.1016/j.ejpn.2017.04.733]">Borggraefe 2013</a> presented data on the proportion of participants seizureâfree at six months. The results for whether there was an effect of sulthiame for seizure freedom were inconclusive. </p> <p>The adverse effects of STM compared with placebo were reported incompletely by <a href="./references#CD010062-bbs2-0004" title='BastT , VÃ¶lpA , WolfC , RatingD . The influence of sulthiame on EEG in children with benign epilepsy with centrotemporal spikes (BECTS). Epilepsia2003;44(2):215-20. [PMID: 12558577]RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6-month randomized, double-blind, placebo-controlled study. Epilepsia2000;41(10):1284-8. [PMID: 11051123]RatingD , WolfC . Sulthiame vs placebo in the treatment of benign epilepsy with centrotemporal spikes ("rolandic" epilepsy). Epilepsia1999;40(Suppl 2):163. '>Rating 1999</a>, precluding the drawing of any meaningful conclusions. <a href="./references#CD010062-bbs2-0003" title="Li Jimin, Li Zuohan, Jin Yongqing, Pan Daoming, Xu Peixi, Hu Dameng, Xu Min. A randomized controlled multicenter clinical study on sulthiame in the treatment of GTCS. Journal of Clinical Neurology2000;13(6):345-7. ">Li 2000</a> reported data on adverse effects of STM compared with PHT, in which the intervention group was combined with a large group of participants who received STM openly and comprised a disproportionately large number of males. <a href="./references#CD010062-bbs2-0003" title="Li Jimin, Li Zuohan, Jin Yongqing, Pan Daoming, Xu Peixi, Hu Dameng, Xu Min. A randomized controlled multicenter clinical study on sulthiame in the treatment of GTCS. Journal of Clinical Neurology2000;13(6):345-7. ">Li 2000</a> reported data suggesting that there was no significant difference in the overall occurrence of adverse effects between STM and PHT groups; however, the occurrence of gingival hyperplasia was significantly greater in the PHT group. The study reported no significant difference in the occurrence of paraesthesia, dizziness, headache, anorexia, rash, or other adverse effects between the STM and PHT groups. <a href="./references#CD010062-bbs2-0001" title="BasnecA , SkarpaD , BarisicN , JurinM , Mucic-PucicB . The risk of second seizure in children with benign childhood epilepsy with centrotemporal spikes without treatment - a prospective study [Rizik javljanja drugog napadaja u nelijeÄene djece s benignom parcijalnom epilepsijom s centrotemporalnim Å¡iljaka - prospektivno istraÅ¾ivanje]. Acta Medica Croatica2005;59(1):59-62. [PMID: 15813357]">Basnec 2005</a> reported none of our prespecified outcomes. <a href="./references#CD010062-bbs2-0002" title="BorggraefeI , BonfertM , BastT , NeubauerBA , SchottenKJ , MassmannK , et al. Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study). European Journal of Paediatric Neurology2013;17(5):507-14. [DOI: 10.1016/j.ejpn.2013.03.014] [PMID: 23642492]BorggraefeI , BonfertM , GerstlL , HeinenF , NeubauerB . A double-blinded, randomized evaluation of neuropsychological and behavioral changes in children with benign epilepsy with centrotemporal spikes treated either with levetiracetam or sulthiame. Epilepsy Currents2015;15(Suppl 1):278, Abstract no: 2.04. TackeM , BorggraefeI , GerstlL , HeinenF , VillK , BonfertM , et al. Effects of levetiracetam and sulthiame on EEG in benign epilepsy with centrotemporal spikes: a randomized controlled trial. Seizure2018;56:115-20. [DOI: 10.1016/j.seizure.2018.01.015] [PMID: 29475094]TackeM , GerstlL , HeinenF , HeukaeuferI , BonfertM , BastT , et al. Effect of anticonvulsive treatment on neuropsychological performance in children with BECTS. European Journal of Paediatric Neurology2016;20(6):874-9. [DOI: 10.1016/j.ejpn.2016.07.015] [PMID: 27553576]TackeM . EEG changes in rolandic epilepsy under treatment with levetiracetam and sulthiame. European Journal of Paediatric Neurology2017;21(Suppl 1):e97, Abstract no: P2-5. [DOI: 10.1016/j.ejpn.2017.04.733]">Borggraefe 2013</a> reported data on adverse effects of STM compared with LEV. Total adverse reactions was higher in the LEV group compared to the STM group, though not reaching statistical significance. The most common adverse events were related to behavioural disturbances (depression, restlessness, irritability, anxiety, change of personality, aggressive behaviour), with the same incidence in both groups. In addition, there was a higher incidence of adverse events affecting the airways (shortness of breathing, tachypnoea, coughing, irritability of upper airway tract) in the STM group. The study reported no significant difference between groups for the other adverse reactions: general symptoms (weight gain or loss, sleep disorder, fatigue, skin lesions, hiccup), central nervous system (headache, vertigo, tremor, paraesthesia, ataxia, diplopia, amnesia, impairment of alertness) (<a href="./references#CD010062-fig-0008" title="">Analysis 1.4</a>), cardiac (pain, tachycardia), gastrointestinal (abdominal pain, loss of appetite, indigestion, nausea, vomiting, diarrhoea), bones and muscles (bone and joint pain, muscle pain), or other adverse effects (gingivitis, alopecia, gingival bleeding, hyperacusis, dry skin). </p> </section> <section id="CD010062-sec-0077"> <h3 class="title" id="CD010062-sec-0077">Overall completeness and applicability of evidence</h3> <p>This review included two studies (<a href="./references#CD010062-bbs2-0004" title='BastT , VÃ¶lpA , WolfC , RatingD . The influence of sulthiame on EEG in children with benign epilepsy with centrotemporal spikes (BECTS). Epilepsia2003;44(2):215-20. [PMID: 12558577]RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6-month randomized, double-blind, placebo-controlled study. Epilepsia2000;41(10):1284-8. [PMID: 11051123]RatingD , WolfC . Sulthiame vs placebo in the treatment of benign epilepsy with centrotemporal spikes ("rolandic" epilepsy). Epilepsia1999;40(Suppl 2):163. '>Rating 1999</a>; <a href="./references#CD010062-bbs2-0001" title="BasnecA , SkarpaD , BarisicN , JurinM , Mucic-PucicB . The risk of second seizure in children with benign childhood epilepsy with centrotemporal spikes without treatment - a prospective study [Rizik javljanja drugog napadaja u nelijeÄene djece s benignom parcijalnom epilepsijom s centrotemporalnim Å¡iljaka - prospektivno istraÅ¾ivanje]. Acta Medica Croatica2005;59(1):59-62. [PMID: 15813357]">Basnec 2005</a>) that compared STM as monotherapy versus placebo in participants with a diagnosis of BECTS; one study that compared STM as monotherapy versus PHT in participants with a history of GTCS (<a href="./references#CD010062-bbs2-0003" title="Li Jimin, Li Zuohan, Jin Yongqing, Pan Daoming, Xu Peixi, Hu Dameng, Xu Min. A randomized controlled multicenter clinical study on sulthiame in the treatment of GTCS. Journal of Clinical Neurology2000;13(6):345-7. ">Li 2000</a>); and one study that compared STM as monotherapy versus LEV in children with BECTS (<a href="./references#CD010062-bbs2-0002" title="BorggraefeI , BonfertM , BastT , NeubauerBA , SchottenKJ , MassmannK , et al. Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study). European Journal of Paediatric Neurology2013;17(5):507-14. [DOI: 10.1016/j.ejpn.2013.03.014] [PMID: 23642492]BorggraefeI , BonfertM , GerstlL , HeinenF , NeubauerB . A double-blinded, randomized evaluation of neuropsychological and behavioral changes in children with benign epilepsy with centrotemporal spikes treated either with levetiracetam or sulthiame. Epilepsy Currents2015;15(Suppl 1):278, Abstract no: 2.04. TackeM , BorggraefeI , GerstlL , HeinenF , VillK , BonfertM , et al. Effects of levetiracetam and sulthiame on EEG in benign epilepsy with centrotemporal spikes: a randomized controlled trial. Seizure2018;56:115-20. [DOI: 10.1016/j.seizure.2018.01.015] [PMID: 29475094]TackeM , GerstlL , HeinenF , HeukaeuferI , BonfertM , BastT , et al. Effect of anticonvulsive treatment on neuropsychological performance in children with BECTS. European Journal of Paediatric Neurology2016;20(6):874-9. [DOI: 10.1016/j.ejpn.2016.07.015] [PMID: 27553576]TackeM . EEG changes in rolandic epilepsy under treatment with levetiracetam and sulthiame. European Journal of Paediatric Neurology2017;21(Suppl 1):e97, Abstract no: P2-5. [DOI: 10.1016/j.ejpn.2017.04.733]">Borggraefe 2013</a>). We were unable to adequately assess the methodological quality and the full range of data of <a href="./references#CD010062-bbs2-0001" title="BasnecA , SkarpaD , BarisicN , JurinM , Mucic-PucicB . The risk of second seizure in children with benign childhood epilepsy with centrotemporal spikes without treatment - a prospective study [Rizik javljanja drugog napadaja u nelijeÄene djece s benignom parcijalnom epilepsijom s centrotemporalnim Å¡iljaka - prospektivno istraÅ¾ivanje]. Acta Medica Croatica2005;59(1):59-62. [PMID: 15813357]">Basnec 2005</a> because a reliable English translation of the published paper could not be obtained. <a href="./references#CD010062-bbs2-0004" title='BastT , VÃ¶lpA , WolfC , RatingD . The influence of sulthiame on EEG in children with benign epilepsy with centrotemporal spikes (BECTS). Epilepsia2003;44(2):215-20. [PMID: 12558577]RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6-month randomized, double-blind, placebo-controlled study. Epilepsia2000;41(10):1284-8. [PMID: 11051123]RatingD , WolfC . Sulthiame vs placebo in the treatment of benign epilepsy with centrotemporal spikes ("rolandic" epilepsy). Epilepsia1999;40(Suppl 2):163. '>Rating 1999</a> clearly stated their inclusion and exclusion criteria and provided a satisfactory explanation of a methodologically sound randomised controlled trial. </p> <p>We downgraded the certainty of evidence to low for the primary outcome treatment withdrawal. The certainty of evidence for the secondary outcomes, seizure freedom and adverse effects, was low. We downgraded the certainty of the evidence to low because of small sample size, lack of clarity on whether intentionâtoâtreat analysis was performed, and the absence of important outcome measures. </p> <p>Given that data on important outcome measures were lacking in some studies, sample sizes were small, and methodology was unclear in the included studies, little clinical relevance can be attributed to this review at this time. </p> </section> <section id="CD010062-sec-0078"> <h3 class="title" id="CD010062-sec-0078">Quality of the evidence</h3> <p>Overall, we assessed one study at high risk of bias and one study at unclear bias across the seven domains, mainly due to lack of information regarding study design. Only one trial reported effective methods for blinding. The risk of bias assessments for the other two studies ranged from low to high. </p> <p>We used the GRADE approach to rate the certainty of evidence for each outcome. The assessments are presented in a summary of findings tables (see <a href="./full#CD010062-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD010062-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD010062-tbl-0003">summary of findings Table 3</a>). We judged the certainty of the evidence for adverse effects as low given that the numbers of events reported were insufficient to draw any conclusions. </p> </section> <section id="CD010062-sec-0079"> <h3 class="title" id="CD010062-sec-0079">Potential biases in the review process</h3> <p>Although we requested protocols for all of the included studies, the time frame in which the majority of the studies were conducted made retrieval of these difficult. This could lead to potential bias through omitted information to which we did not have access. </p> </section> <section id="CD010062-sec-0080"> <h3 class="title" id="CD010062-sec-0080">Agreements and disagreements with other studies or reviews</h3> <p>We found no reviews or published information on the use of sulthiame as monotherapy for epilepsy. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010062-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/urn:x-wiley:14651858:media:CD010062:CD010062-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD010062-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_t/tCD010062-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/full#CD010062-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010062-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/urn:x-wiley:14651858:media:CD010062:CD010062-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010062-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_t/tCD010062-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/full#CD010062-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010062-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/urn:x-wiley:14651858:media:CD010062:CD010062-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010062-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_t/tCD010062-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/full#CD010062-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010062-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/urn:x-wiley:14651858:media:CD010062:CD010062-FIG-04" target="_blank"><b></b></a></p> </div><img alt="ORBIT table" data-id="CD010062-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-FIG-04.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_t/tCD010062-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>ORBIT table</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/full#CD010062-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-FIG-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010062-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/urn:x-wiley:14651858:media:CD010062:CD010062-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Sulthiame versus levetiracetam, Outcome 1: Treatment withdrawal" data-id="CD010062-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_t/tCD010062-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Sulthiame versus levetiracetam, Outcome 1: Treatment withdrawal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/references#CD010062-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010062-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/urn:x-wiley:14651858:media:CD010062:CD010062-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Sulthiame versus levetiracetam, Outcome 2: Seizure freedom" data-id="CD010062-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_t/tCD010062-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Sulthiame versus levetiracetam, Outcome 2: Seizure freedom</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/references#CD010062-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010062-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/urn:x-wiley:14651858:media:CD010062:CD010062-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Sulthiame versus levetiracetam, Outcome 3: General symptoms (weight gain or loss, sleep disorder, fatigue, skin lesions, hiccups)" data-id="CD010062-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_t/tCD010062-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Sulthiame versus levetiracetam, Outcome 3: General symptoms (weight gain or loss, sleep disorder, fatigue, skin lesions, hiccups) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/references#CD010062-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010062-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/urn:x-wiley:14651858:media:CD010062:CD010062-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Sulthiame versus levetiracetam, Outcome 4: Central nervous system (headache, vertigo, tremor, paraesthesia, ataxia, diplopia, amnesia, impairment of alertness)" data-id="CD010062-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_t/tCD010062-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Sulthiame versus levetiracetam, Outcome 4: Central nervous system (headache, vertigo, tremor, paraesthesia, ataxia, diplopia, amnesia, impairment of alertness) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/references#CD010062-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010062-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/urn:x-wiley:14651858:media:CD010062:CD010062-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Sulthiame versus levetiracetam, Outcome 5: Behaviour (depression, restlessness, irritability, anxiety, change of personality, aggressive behaviour)" data-id="CD010062-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_t/tCD010062-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Sulthiame versus levetiracetam, Outcome 5: Behaviour (depression, restlessness, irritability, anxiety, change of personality, aggressive behaviour) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/references#CD010062-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010062-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/urn:x-wiley:14651858:media:CD010062:CD010062-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Sulthiame versus levetiracetam, Outcome 6: Airways (shortness of breathing, tachypnoea, coughing, irritability of upper airway tract)" data-id="CD010062-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_t/tCD010062-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Sulthiame versus levetiracetam, Outcome 6: Airways (shortness of breathing, tachypnoea, coughing, irritability of upper airway tract) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/references#CD010062-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010062-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/urn:x-wiley:14651858:media:CD010062:CD010062-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Sulthiame versus levetiracetam, Outcome 7: Cardiac (pain, tachycardia)" data-id="CD010062-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_t/tCD010062-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Sulthiame versus levetiracetam, Outcome 7: Cardiac (pain, tachycardia)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/references#CD010062-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010062-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/urn:x-wiley:14651858:media:CD010062:CD010062-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Sulthiame versus levetiracetam, Outcome 8: Gastrointestinal (abdominal pain, loss of appetite, indigestion, nausea, vomiting, diarrhoea)" data-id="CD010062-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_t/tCD010062-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Sulthiame versus levetiracetam, Outcome 8: Gastrointestinal (abdominal pain, loss of appetite, indigestion, nausea, vomiting, diarrhoea) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/references#CD010062-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010062-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/urn:x-wiley:14651858:media:CD010062:CD010062-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Sulthiame versus levetiracetam, Outcome 9: Bones and muscles (bone and joint pain, muscle pain)" data-id="CD010062-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_t/tCD010062-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Sulthiame versus levetiracetam, Outcome 9: Bones and muscles (bone and joint pain, muscle pain) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/references#CD010062-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010062-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/urn:x-wiley:14651858:media:CD010062:CD010062-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Sulthiame versus levetiracetam, Outcome 10: Others (gingivitis, alopecia, gingival bleeding, hyperacusis, dry skin)" data-id="CD010062-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_t/tCD010062-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Sulthiame versus levetiracetam, Outcome 10: Others (gingivitis, alopecia, gingival bleeding, hyperacusis, dry skin) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/references#CD010062-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010062-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/urn:x-wiley:14651858:media:CD010062:CD010062-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sulthiame versus phenytoin, Outcome 1: All adverse effects" data-id="CD010062-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_t/tCD010062-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Sulthiame versus phenytoin, Outcome 1: All adverse effects</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/references#CD010062-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010062-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/urn:x-wiley:14651858:media:CD010062:CD010062-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sulthiame versus phenytoin, Outcome 2: Paraesthesia" data-id="CD010062-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_t/tCD010062-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Sulthiame versus phenytoin, Outcome 2: Paraesthesia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/references#CD010062-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010062-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/urn:x-wiley:14651858:media:CD010062:CD010062-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sulthiame versus phenytoin, Outcome 3: Dizziness" data-id="CD010062-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_t/tCD010062-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Sulthiame versus phenytoin, Outcome 3: Dizziness</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/references#CD010062-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010062-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/urn:x-wiley:14651858:media:CD010062:CD010062-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sulthiame versus phenytoin, Outcome 4: Headache" data-id="CD010062-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_t/tCD010062-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Sulthiame versus phenytoin, Outcome 4: Headache</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/references#CD010062-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010062-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/urn:x-wiley:14651858:media:CD010062:CD010062-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sulthiame versus phenytoin, Outcome 5: Anorexia" data-id="CD010062-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_t/tCD010062-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Sulthiame versus phenytoin, Outcome 5: Anorexia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/references#CD010062-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010062-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/urn:x-wiley:14651858:media:CD010062:CD010062-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sulthiame versus phenytoin, Outcome 6: Rash" data-id="CD010062-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_t/tCD010062-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Sulthiame versus phenytoin, Outcome 6: Rash</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/references#CD010062-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010062-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/urn:x-wiley:14651858:media:CD010062:CD010062-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sulthiame versus phenytoin, Outcome 7: Gingival hyperplasia" data-id="CD010062-fig-0021" src="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_t/tCD010062-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Sulthiame versus phenytoin, Outcome 7: Gingival hyperplasia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/references#CD010062-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010062-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/urn:x-wiley:14651858:media:CD010062:CD010062-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sulthiame versus phenytoin, Outcome 8: Other" data-id="CD010062-fig-0022" src="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_t/tCD010062-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Sulthiame versus phenytoin, Outcome 8: Other</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/references#CD010062-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/media/CDSR/CD010062/image_n/nCD010062-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010062-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span>Â <span class="table-title">Sulthiame compared to placebo for epilepsy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Sulthiame compared to placebo for epilepsy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with epilepsy </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> sulthiame </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sulthiame</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment withdrawal</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 (2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for treatment withdrawal not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizure freedom</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 (2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for seizure freedom not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All adverse effects</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 (2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for adverse effects not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b><sup>1</sup>(e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>N/A:</b> not applicable </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Assumed risk is calculated as the event rate in the control group per 1000 people (number of events divided by the number of participants receiving control treatment). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span>Â <span class="table-title">Sulthiame compared to placebo for epilepsy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/full#CD010062-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010062-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span>Â <span class="table-title">Sulthiame compared with levetiracetam for epilepsy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Sulthiame compared with levetiracetam for epilepsy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with epilepsy (BECTS) </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> sulthiame </p> <p><b>Comparison:</b> levetiracetam </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sulthiame</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment withdrawal</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>429 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>137 per 1000</b> </p> <p>(43 to 442)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.32</b> (0.10 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single, small study. Data for number of treatment withdrawal provided.</p> <p>RR &lt; 1 indicates outcome is more likely in control group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizure freedom</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>809 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>906 per 1000</b> </p> <p>(712 to 1165)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b> </p> <p>(0.88 to 1.44)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ</p> <p><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single, small study. Data for seizure freedom provided.</p> <p>RR &gt; 1 indicates outcome is more likely in sulthiame group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects (general symptoms)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>714 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>771 per 1000</b> </p> <p>(543 to 1100)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b> (0.76 to 1.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single, small study. Data for number of adverse events provided.</p> <p>RR &gt; 1 indicates outcome is more likely in sulthiame group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects (central nervous system)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>619 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>724 per 1000</b> </p> <p>(477 to 1108)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.17</b> (0.77 to 1.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single, small study. Data for number of adverse</p> <p>events provided.</p> <p>RR &gt; 1 indicates outcome is more likely in sulthiame</p> <p>group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects (behaviour)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>619 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>588 per 1000</b> </p> <p>(365 to 959)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b> (0.59 to 1.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single, small study. Data for number of adverse events provided.</p> <p>RR &lt; 1 indicates outcome is more likely in control</p> <p>group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects (airways)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>238 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>636 per 1000</b> </p> <p>(279 to 1457)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.67</b> (1.17 to 6.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single, small study. Data for number of adverse</p> <p>events provided.</p> <p>RR &gt; 1 indicates outcome is more likely in sulthiame</p> <p>group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects (cardiac)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> <p>(0 to 0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.87</b> (0.12 to 66.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single, small study. Data for number of adverse</p> <p>events provided.</p> <p>RR &gt; 1 indicates outcome is more likely in sulthiame</p> <p>group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects (gastrointestinal)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>576 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>438 per 1000</b> </p> <p>(213 to 899)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.76</b> (0.37 to 1.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single, small study. Data for number of adverse</p> <p>events provided.</p> <p>RR &lt; 1 indicates outcome is more likely in control</p> <p>group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects (bones and muscles)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>191 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>182 per 1000</b> </p> <p>(52 to 636)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b> (0.27 to 3.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single, small study. Data for number of adverse events provided.</p> <p>RR &lt; 1 indicates outcome is more likely in control</p> <p>group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects (others)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>191 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>227 per 1000</b> </p> <p>(71 to 735)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.19</b> (0.37 to 3.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single, small study. Data for number of adverse events provided.</p> <p>RR &gt; 1 indicates outcome is more likely in sulthiame</p> <p>group.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b><sup>3</sup> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>BECTS:</b> benign epilepsy of childhood with centrotemporal spikes; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded once for risk of bias: some included studies had incomplete methodological information.<br/><sup>2</sup>Downgraded once for imprecision: number of events does not suffice for optimal information size.<br/><sup>3</sup>Assumed risk is calculated as the event rate in the control group per 1000 people (number of events divided by the number of participants receiving control treatment). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span>Â <span class="table-title">Sulthiame compared with levetiracetam for epilepsy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/full#CD010062-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010062-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span>Â <span class="table-title">Sulthiame compared with phenytoin for epilepsy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Sulthiame compared with phenytoin for epilepsy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with epilepsy (GTCS) </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> sulthiame </p> <p><b>Comparison:</b> phenytoin </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sulthiame</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment withdrawal</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> <p>(0 to 0)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> <p>(0 to 0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for treatment withdrawal not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizure freedom</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for seizure freedom not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All adverse effects</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>250 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>263 per 1000</b><br/>(135 to 517) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b> (0.54 to 2.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single study. Data for number of adverse events provided. Unclear if data on adverse events reflect number of events or number of participants experiencing an event. </p> <p>RR &gt; 1 indicates outcome is more likely in sulthiame group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Paraesthesia</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>123 per 1000</b><br/>(0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 8.32</b> (0.51 to 135.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single study. Data for number of adverse events provided. Unclear if data on adverse events reflect number of events or number of participants experiencing an event. </p> <p>RR &gt; 1 indicates outcome is more likely in sulthiame group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dizziness</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 1000</b><br/>(0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.16</b> (0.18 to 55.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single study. Data for number of adverse events provided. Unclear if data on adverse events reflect number of events or number of participants experiencing an event. </p> <p>RR &gt; 1 indicates outcome is more likely in sulthiame group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Headache</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b><br/>(0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.43</b> (0.07 to 29.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single study. Data for number of adverse events provided. Unclear if data on adverse events reflect number of events or number of participants experiencing an event. </p> <p>RR &gt; 1 indicates outcome is more likely in sulthiame group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Anorexia</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>63 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>26 per 1000</b><br/>(4 to 152) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.42</b> (0.07 to 2.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single study. Data for number of adverse events provided. Unclear if data on adverse events reflect number of events or number of participants experiencing an event. </p> <p>RR &lt; 1 indicates outcome is more likely in control group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rash</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b><br/>(1 to 135) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.28</b> (0.02 to 4.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single study. Data for number of adverse events provided. Unclear if data on adverse events reflect number of events or number of participants experiencing an event. </p> <p>RR &lt; 1 indicates outcome is more likely in control group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gingival hyperplasia</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>125 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b><br/>(0 to 72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.03</b> (0.00 to 0.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single study. Data for number of adverse events provided. Unclear if data on adverse events reflect number of events or number of participants experiencing an event. </p> <p>RR &lt; 1 indicates outcome is more likely in control group.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>43 per 1000</b><br/>(5 to 359) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.40</b> (0.17 to 11.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ââââ<br/><b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single study. Data for number of adverse events provided. Unclear if data on adverse events reflect number of events or number of participants experiencing an event. </p> <p>RR &gt; 1 indicates outcome is more likely in sulthiame group.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b><sup>3</sup>(e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>GTCS:</b> generalised tonicâclonic seizures; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded once for risk of bias: one included study had incomplete methodological information.<br/><sup>2</sup>Downgraded once for imprecision: number of events does not suffice for optimal information size.<br/><sup>3</sup>Assumed risk is calculated as the event rate in the control group per 1000 people (number of events divided by the number of participants receiving control treatment). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span>Â <span class="table-title">Sulthiame compared with phenytoin for epilepsy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/full#CD010062-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010062-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span>Â <span class="table-title">Sulthiame versus levetiracetam</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Treatment withdrawal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.10, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Seizure freedom <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.88, 1.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 General symptoms (weight gain or loss, sleep disorder, fatigue, skin lesions, hiccups) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.76, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Central nervous system (headache, vertigo, tremor, paraesthesia, ataxia, diplopia, amnesia, impairment of alertness) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.77, 1.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Behaviour (depression, restlessness, irritability, anxiety, change of personality, aggressive behaviour) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.59, 1.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Airways (shortness of breathing, tachypnoea, coughing, irritability of upper airway tract) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.67 [1.17, 6.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Cardiac (pain, tachycardia) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.87 [0.12, 66.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Gastrointestinal (abdominal pain, loss of appetite, indigestion, nausea, vomiting, diarrhoea) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.37, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Bones and muscles (bone and joint pain, muscle pain) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.27, 3.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Others (gingivitis, alopecia, gingival bleeding, hyperacusis, dry skin) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.37, 3.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span>Â <span class="table-title">Sulthiame versus levetiracetam</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/references#CD010062-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010062-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span>Â <span class="table-title">Sulthiame versus phenytoin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 All adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.54, 2.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Paraesthesia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.32 [0.51, 135.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Dizziness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.16 [0.18, 55.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.07, 29.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Anorexia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.07, 2.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Rash <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.02, 4.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Gingival hyperplasia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [0.00, 0.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Other <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.17, 11.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span>Â <span class="table-title">Sulthiame versus phenytoin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010062.pub3/references#CD010062-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010062.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010062-note-0009">EspaÃ±ol</a> </li> <li class="section-language"> <a class="" href="fa#CD010062-note-0006">ÙØ§Ø±Ø³Û</a> </li> <li class="section-language"> <a class="" href="fr#CD010062-note-0007">FranÃ§ais</a> </li> <li class="section-language"> <a class="" href="ms#CD010062-note-0008">Bahasa Malaysia</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright Â© 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">Â Â Facebook</a> <a class="a2a_button_x share-button">Â Â X(Twitter)</a> <a class="a2a_button_whatsapp share-button">Â Â WhatsApp</a> <a class="a2a_dd share-button">Â Â View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010062\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010062\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010062\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010062\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010062\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010062\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010062\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010062\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010062\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010062\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010062\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010062\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010062\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010062\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010062\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010062\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010062\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010062\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1ljSZou6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010062.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010062.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">EspaÃ±ol</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">ÙØ§Ø±Ø³Û</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">FranÃ§ais</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">à¤¹à¤¿à¤¨à¥à¤¦à¥</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">æ¥æ¬èª</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">íêµ­ì´</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">PortuguÃªs</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Ð ÑÑÑÐºÐ¸Ð¹</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">RomÃ¢nÄ</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">à®¤à®®à®¿à®´à¯</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">à¸ à¸²à¸©à¸²à¹à¸à¸¢</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">ç¹é«ä¸­æ</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">ç®ä½ä¸­æ</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010062.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010062.pub3/full/es">EspaÃ±ol</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010062.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728596302"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010062.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728596306"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010062.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ec855eb72f431',t:'MTc0MDcyODU5Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 